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General introduction
Abdominal aortic aneurysms
An abdominal aortic aneurysm is a localised, permanent dilatation of the 
abdominal aorta that exceeds the normal diameter by more than 50 percent. 
Abdominal aortic aneurysms (AAAs) are a significant health challenge with 
an estimated incidence of 20-40 cases per 100 000 population per year. Initial 
treatment is aimed at preventing rupture.1,2 There is a generally accepted indication 
for treatment if the threshold diameter of the AAA is reached (55 mm/50 mm, 
measured by ultrasonography, in males/females respectively), if rapid aneurysm 
growth is observed (> 5 mm / 6 months), or if the aneurysm becomes symptomatic.3
Open aneurysm repair
Since its first introduction in 1952 by Dubost et al., open aneurysm repair has 
undergone many improvements and has become the gold standard of AAA 
treatment.4 Based on long-term follow-up data, open repair remains a safe 
and durable option for the management of AAAs.5 However, open surgical 
aneurysm repair requires laparotomy and clamping of the aorta, which is 
frequently accompanied by substantial blood loss. Consequently, open repair is 
still associated with a perioperative mortality rate of 2% to 5% and significant 
morbidity. 
Endovascular aneurysm repair (EVAR)
Over the last 25 years, the management of AAAs has changed dramatically. 
Independently of each other, Parodi et al. and Volodos et al. introduced endovascular 
aneurysm repair (EVAR) in 1991.6,7 Under X-ray fluoroscopic guidance, a minimally 
invasive approach is used to introduce a stent graft into the abdominal aorta 
and exclude the aneurysm sac from circulation. Initially, EVAR was an alternative 
treatment for patients with severe comorbidities, who were not suitable for open 
repair. Currently, however, EVAR has become the preferred treatment option for 
patients with an AAA in many centres. However, the main downside of EVAR is the 
risk of late complications and the subsequent need for secondary interventions.8
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Stent graft related complications
Type-I endoleak
A type-I endoleak is defined as blood flow into the aneurysm due to an 
incomplete or ineffective seal at the stent graft ends. The blood flow is direct and 
under systemic pressure. The AAA is not excluded from circulation anymore and 
therefore at risk of continued expansion and rupture. AAAs with short, angulated 
and heavily calcified infrarenal necks are at increased risk.9 If type-I endoleaks 
are observed during the initial procedure, they should be corrected before the 
patient leaves the operating theatre. Intraoperative and late type-I endoleaks 
can be resolved through additional ballooning at the proximal attachment site, 
placement of balloon expandable stents, or stent-graft extension.10-13
Type-II endoleak
The most common form of endoleaks after infrarenal EVAR are type-II endoleaks, 
which are defined as branch flow through a patent inferior mesenteric artery (IMA), 
lumbar artery, accessory renal artery, or hypogastric artery. Type-II endoleaks show 
an incidence of 15 to 20% perioperatively and at one month postoperatively. At 
1-year follow-up, the incidence decreases to 5 to 10% .14 The most common source 
of type-II endoleaks is through lumbar arteries and via the inferior mesenteric 
artery (IMA). Nowadays, a much more conservative approach is accepted regarding 
type-II endoleak management, because many of them seems to be relatively 
benign.15 Some type-II endoleaks tend to resolve spontaneously, while others 
persist without causing clinical symptoms and a small proportion may cause 
significant increase in sac size.16 If reparation of a type-II endoleak is considered 
necessary, embolization may be executed with a transarterial approach or with 
direct endoleak puncture by means of a translumbar approach.17-19
Type-III endoleak
Type-III endoleaks are defined as mid-graft endoleaks that originate either from 
fabric holes or from an inadequate seal between endograft components. The 
incidence of type-III endoleaks is between 0.1 and 6.4 percent. To avoid inadequate 
seals, it is vital to use sufficient component overlap during the primary procedure, 
particularly in case of severe tortuosity of the iliac arteries or extreme neck 
angulation, which result in significantly increased forces on the overlap. A type-III 
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endoleak can be eliminated by using additional stent graft components to bridge 
the defect.20
Type-IV endoleak
A type-IV endoleak is present if blood or fluid passes through the graft fabric due 
to porosity of the stent graft, a phenomenon that was recognized in the early 
period of stent grafting as generally taking place immediately after implantation.21 
Type-IV endoleaks generally require no secondary intervention, as they are usually 
longer observed at the first surveillance CTA. 
Migration
Stent graft migration is defined as stent graft movement of > 10 mm relative to 
anatomical landmarks or any migration leading to symptoms or requiring therapy.8 
Risk of migration increases over time and can result in loss of device fixation 
proximally, distally, or at modular junctions.22 Stent graft migration may result 
in a type 1 endoleak with repressuration of the aneurysm sac, which can lead to 
rupture. Factors that contribute to migration are aortic neck and AAA morphology, 
insufficient accuracy of stent graft deployment, post-operative neck enlargement, 
proximal attachment failure, iliac fixation, and characteristics of stent grafts.3
The proximal type-I endoleak is the most important cause of AAA rupture after 
initial aneurysm exclusion with EVAR. Both type-I endoleaks and migration are the 
most common reasons for re-interventions. Complications can occur early or late 
during follow-up, therefore long-term follow-up is required after EVAR.23 
Anatomic limitations
The success of EVAR, in terms of exclusion of the aneurysm and absence of 
perioperative and postoperative complications, is closely dependent on the 
morphology and dimensions of the AAA.24,25 For this reason, the instructions 
for use (IFU) of all commercially available stent grafts include strict guidelines 
regarding AAA morphology and dimensions. If these guidelines were followed in 
daily practice, EVAR would be withheld from approximately 40% of patients with 
an AAA. Global registries show that EVAR is performed in patients whose anatomy 
is outside the recommended limits.26 
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Evolution of stent grafts
The first generation stent grafts led to significant problems during follow-up, 
including progressive neck dilatation, distal migration, modular separation, 
thrombosis, and loss of integrity.27,28 Substantial progress has been made with new 
generation devices to prevent such complications.29-32 This progress has continued 
up to the newest generation of stent grafts, which show good results in terms 
of perioperative and postoperative outcome, even in patients with a challenging 
anatomy.26,33
Stent graft manufacturers continue to refine both the stent graft and its delivery 
system. Besides, the physicians experience has increased over the past decades. 
Experienced vascular surgeons dare to take on aneurysms with short and 
angulated necks, thus allowing a wider range of patients to be treated with EVAR. 
Emergency EVAR
EVAR has become the preferred treatment option in patients with a ruptured AAA 
in many centres worldwide. The technical success of EVAR depends on accurate 
preoperative planning, including aortic aneurysm sizing and adequate stent graft 
selection. In patients presenting with a ruptured AAA (RAAA), planning has to 
be done under pressure and in a limited time frame. Usually there is no time 
for extensive image reconstructions with a dedicated measuring programme. In 
addition, the stent graft will have to be selected from an available stock that will 
be at least relatively limited. Due to the nature of RAAAs and the concomitant 
hemodynamic instability, it is reasonable to assume that the interventionist will 
speed up the procedure to reach adequate haemostasis as soon as possible. All 
these factors can influence the procedure and can have an effect on the safety, 
durability and effectiveness of the stent graft in both short-term and long-term 
outcomes. 
AAA repair in very unstable patients
A patient-specific treatment strategy may possibly improve the outcome if the 
selection criteria for the intervention are optimized. Scoring systems combining 
clinical findings and biochemical results were introduced as a means to predict 
survival for RAAA patients. For instance, the Hardman index uses a set of five 
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parameters. Although this index is easily applicable, the outcome may also be 
determined by other factors.34 To date, there is no single system that allows for 
a proper preoperative selection of candidates who might optimally benefit from 
vascular surgery for RAAA. However, the necessity of preoperative cardiopulmonary 
resuscitation (CPR) reflects a dismal condition in an RAAA patient. Therefore, it is 
highly questionable whether RAAA patients requiring preoperative CPR should be 
offered surgical treatment at all. A slim body of low-level literature suggests that 
these patients are unlikely to survive.35-37
Aim of the thesis
• To assess the occurrence of graft-related complications and secondary 
interventions during a minimum of ten years of follow-up.
• To compare EVAR in patients with ruptured and non-ruptured AAAs in a 
retrospective, single-centre study.
• To assess the effects of anaesthesia type on the outcome of elective EVAR in a 
multi-centre, non-randomized, prospective observational study.
• To evaluate clinical outcome in RAAA patients who received cardiopulmonary 
resuscitation (CPR) prior to surgery.
• To assess the effect of challenging AAA morphology on the outcomes of 
elective EVAR in a multi-centre, non-randomized, prospective observational 
study.
• To assess the effects of challenging infrarenal aortic necks in patients with a 
RAAA treated with EVAR.
• To set up a protocol to prospectively collect real-world data on patients with 
challenging infrarenal aortic necks treated with the newest generation stent 
graft.
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Outline of the thesis
This thesis consists of three parts. Part I focuses on the outcomes of elective 
and emergency EVAR (chapters 2 and 3). The second part of this thesis contains 
studies on perioperative care and emergency EVAR in highly unstable patients 
(chapters 4 and 5). Once the clinical outcomes and new insights into perioperative 
management in EVAR have been described, part 3 focuses on the outcome of EVAR 
in patients with challenging proximal aortic neck anatomy (chapters 6, 7 and 8). 
PART ONE - Evolution and long-term follow-up in EVAR
The main downside of EVAR is the risk of late complications and the need for 
secondary interventions. Therefore, lifelong surveillance is advised after EVAR. 
However, there is little evidence on long-term stent graft durability to support this 
intensive and costly follow-up recommendation. Chapter 2 reports 10-year follow-
up data of elective cases of EVAR with the Talent infrarenal stent graft (Medtronic 
Vascular, Santa Rosa, CA, USA). To assess the need of lifelong surveillance after 
EVAR, we evaluated the occurrence of stent graft related complications and 
secondary interventions during a minimum of ten-year follow-up.
To evaluate and compare the technical performance of EVAR in both an elective 
as well as an emergency setting, we analysed outcomes of all EVAR procedures in 
the Catharina Hospital Eindhoven over a 15-year period. As described in Chapter 
3, we evaluated technical operation success rates and compared the occurrence 
of secondary interventions after elective and emergency EVAR.
PART TWO - Clinical experience and new insights regarding EVAR
Chapter 4 presents an observational study that compared EVAR cases performed 
under different types of anaesthesia. The feasibility of EVAR with local and 
regional anaesthesia was already proven in 1999.38 Guidelines recommend the 
use of locoregional anaesthesia for EVAR if possible.3,39 Nevertheless, EVAR is still 
mainly performed under general anaesthesia.40 Technical operation success and 
thirty-day outcomes were evaluated in this chapter. 
Surgical repair of RAAAs is not always possible, due to existing comorbidities, 
anatomic unsuitability or a highly unstable patient condition at the time of 
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admission. Chapter 5 evaluates the outcomes of RAAA in patients requiring 
preoperative cardiopulmonary resuscitation. Since EVAR is clearly less invasive 
than an open reconstruction, feasible under local anaesthesia, and certainly 
much quicker if performed by an experienced surgeon, we also analysed which 
technique appears to be superior in these patients.
PART THREE - Challenging anatomy in EVAR
Chapter 6 describes the outcome of endovascular treatment of RAAAs with short 
and angulated necks based on the experience of a single-centre. In contrast, 
Chapter 7 evaluates outcomes of EVAR by comparing three groups of patients with 
non-ruptured AAAs with different degrees of aortic neck complexity. To date, there 
are no prospective registries on patients treated with challenging aortic necks. For 
this reason, we initiated a multi-centre, prospective, non-randomized registry to 
collect global ‘real-world’ performance data of EVAR in anatomically challenging 
AAAs. Chapter 8 describes the rationale and design of the EAGLE registry (Endurant 
for challenging Anatomy: GLobal Experience). 
PART FOUR - Summary, general discussion and future perspectives
Chapter 9 presents the main results and conclusions of this thesis. We discuss 
both the current knowledge and the remaining controversies and present the 
future perspectives. 
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Abstract
Objective: Yearly lifelong surveillance is advised after endovascular abdominal 
aortic aneurysm repair (EVAR) for abdominal aortic aneurysms (AAA). However, 
this follow-up requires a substantial amount of healthcare resources. The aim of 
this paper was to assess the occurrence of stent graft related complications and 
secondary interventions during a minimum of ten-year follow-up after elective 
EVAR.
Methods: Patients treated in a high-volume endovascular centre in the Netherlands 
with the Talent infrarenal stent graft (Medtronic Vascular, Santa Rosa, CA, USA) 
between June 1999 and February 2005 were included. Patients with previous aortic 
surgery, aortic fistula’s or ruptured AAAs were excluded for this analysis. Our 
primary outcome was clinical success up to 10-years. Secondary endpoints were 
technical success and survival.
Results: A total of 149 patients were included in this study, 91.9% male with a 
mean age of 70.2 ± 7.8 years. A stent graft was implanted in 98% of patients; 
technical success was 89.3%. Clinical success at 30-days, 1, 5 and 10-years was 
81.1%, 74.3%, 70.3% and 65.5%, respectively. A total of 30 (20.7%) patients required 
a secondary intervention, 80.0% of first secondary interventions occurred within 
the first 5 years. Six late conversions were necessary due to; stent graft infection 
(2), migration (2), and persisting endoleak (2). The 5 and 10-year overall survival 
rates were 55.2% and 38.6%, respectively. 
Conclusion: The risk of EVAR related complication is the highest in the first 5-years. 
The main focus must be on that period, further follow-up must not be neglected 
as complications occur up to 10-years after treatment. 
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Introduction
The treatment of aneurysms has changed drastically with the introduction of 
endovascular abdominal aortic aneurysm repair (EVAR) by Parodi et al. in 1991.1 
EVAR has become the preferred method to treat abdominal aortic aneurysms 
(AAA), mainly supported by positive short-term results as opposed to open repair.2, 
3 The main downside of EVAR is the risk of late complications and the subsequent 
need for secondary interventions. Endoleaks, stent graft migration, stent fractures 
and stent graft occlusions may lead to secondary interventions.4, 5 The long-term 
risks require intensive follow-up with yearly visits and imaging of the stent graft.
The evolution of stent graft systems improved applicability and reduced stent graft 
related complications.6 However, current guidelines advise a lifelong surveillance, 
also in modern stent grafts, to timely detect EVAR related complications.7 This 
implies that a young patient would need up to 20 years of follow-up. To date there 
is little evidence on long-term stent graft durability to support these intensive 
and costly follow-up recommendations. We report on a cohort treated ten years 
ago, with a widely used, commercially available, 3rd generation, stent graft.
The aim of this paper is to assess the occurrence of stent graft related complications 
and secondary interventions during a minimum of ten-years of follow-up.
Methods
Study population
This study included patients primarily treated with a Talent Abdominal Stent Graft 
(Medtronic Vascular, Santa Rosa, CA, USA) between June 1999 and February 2005, 
in a tertiary centre for cardiovascular disease in the Netherlands. Only patients 
scheduled for the implantation of a Talent main body, either bifurcated, tube 
or Aortic- Uni-Iliac stent graft, were eligible for inclusion. All data were checked 
against the implantation logbook in order to avoid missing patients. Elective and 
symptomatic patients were included for analysis. Patients with previous aortic 
surgery, aortic fistula’s or ruptured AAAs were excluded for this analysis.
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Data collection
Demographics, preoperative characteristics, comorbidities, and procedure details 
were collected from a prospectively maintained database. The date of death 
was retrieved from hospital records, if absent, the municipal personal records 
were consulted. Additional data was retrieved through referring hospitals or the 
general practitioner was contacted.
Outcomes
The outcomes are defined based on the reporting standards published by Chaikof 
et al..4 The primary outcome is clinical success up to 10-years on an intention-to-
treat basis. Clinical success is defined as the absence of aneurysm related death, 
graft stenosis, occlusion or infection, type-I and III endoleak, aneurysm expansion, 
aneurysm rupture, or conversion to open repair (OR). Graft failure in the form of 
migration, type IV endoleak or other graft integrity disruptions, is regarded as 
clinical failure. Stent graft migration defined as movement of > 10mm. Secondary 
endpoints were technical success and overall survival. Technical success is 
defined as a successful introduction and deployment and the absence of type-I or 
III endoleaks at completion angiography. Aneurysm related mortality included 30-
day mortality and death, either caused by rupture or as the result of a secondary 
intervention. Death after 30-days is reported as late aneurysm related mortality. 
Secondary interventions are defined as all surgical or endovascular interventions 
performed after the index procedure to resolve stent graft related complications. 
Secondary intervention data were analysed on a per protocol basis.
Statistical analysis
Statistical analyses were performed using SPSS version 21 for MAC (IBM 
Corporation, Armonk, NY, USA). Categorical variables are presented as frequencies 
with percentages. Continuous variables are presented as mean ± standard 
deviation or as median and interquartile range (IQR) in case of skewed data. The 
χ2 or Fisher’s exact test were used for categorical variables according to sample 
size. Incidence rates with 95% confidence intervals were determined. A p-value 
< .05 was considered statistically significant. Factors influencing 10-year survival 
were identified using a multivariate regression analysis.
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Results
A total 318 stent grafts were implanted between June 1999 and February 2005. 
In 202 cases a Talent stent graf was implanted, because of ruptures, previous 
aortic surgery, iliac limbs only and aortic fi stulas 53 patients were excluded. 
The baseline characteristics of the 149 included patients are outlined in table 1. 
Patient demographics were typical for an AAA population. A total of 91.9% were 
male with a mean age of 70.2 ± 7.8 years. Survival and secondary intervention data 
on 145 patients were available and comprise the basis for further analysis; there 
were three intraoperative conversions and one patient was lost to follow-up. This 
patient was not included in clinical success analysis.
a Values are reported as mean ± standard deviation, median [IQR], or as frequencies 
(%) (n/N). Denominator differs when there are missing values.
b Groups corrected for conversions and lost to follow-up
AAA, Abdominal Aortic Aneurysm
ASA, American Society of Anaesthesiologists
Table 1. Baseline characteristics.
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Clinical success
A 30-day clinical success was achieved in 81.1% (120/148) of patients. The 30-day 
mortality was 4.7% (7/148); four cardiac, one renal insuffi ciency, one sepsis after 
necrotic cholecystitis and one unknown cause. These patients were signifi cantly 
older (80.3 ± 4.5 vs. 71.1 ± 7.7 p=.001), more frequently suffered from cardiac disease 
(100% vs. 58.% p=.042) and renal insuffi ciency (57.1% vs. 14.2% p=.014). 
Technical success
Intraoperative data is depicted in table 2. The stent graft was successfully 
implanted in 98% (146/149) of the patients. There was an inability to deliver the 
device due to access diffi culties in two female patients, resulting in one direct 
and one delayed conversion to OR. In the third patient, there was a detachment of 
the radiopaque ring from the sheath requiring conversion to OR. Primary assisted 
technical success was achieved in 89.3% (133/149) of the procedures. A total of 
13 patients (8.7%) had a persisting endoleak (12 type-I and one type-III) that was 
accepted on completion angiography. There were no deaths within 24 hours after 
implantation.
a Values are reported as median [IQR], or as frequencies (%) (n/N). Denominator 
differs when there are missing values.
AUI, Aortic-Uni-Iliac graft
LOS, Length of Stay
Table 2. Perioperative outcomes
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The operative endoleaks resolved spontaneously on the first follow-up imaging 
in 76.9% (10/13) of patients. One endoleak required a secondary intervention and 
two patients with an operative endoleak died of cardiac complications within 
30-days. The 1, 5 and 10-year clinical success rates were 74.3%, 70.3% and 65.5%, 
respectively. 
Secondary interventions
The freedom from secondary interventions is presented in a Kaplan-Meier 
curve (Figure 1). Freedom from secondary intervention at 1, 5 and 10-year was 
90.5%, 83.3% and 80.6% respectively. During the complete follow-up, a total of 
38 secondary interventions were required in 30 patients.  In 73.7% of the cases, 
patients were asymptomatic, which means regular follow-up detected the majority 
of complications. Secondary interventions were mainly required for endoleaks, and 
occlusion/stenosis, 57.9%, 15.8% respectively. The need for the initial secondary 
intervention within 1, 5 and 10-years was 60.0%, 80.0% and 100% respectively. 
Three patients required a secondary intervention within 30-days, one for an iliac 
stenosis; one patient had an iliac limb occlusion and one for a type-III endoleak. 
All specific interventions and indications are depicted in table 3. A total of six 
patients were converted to OR during follow-up. The reason for conversion was; 
two stent graft infections, two migrations and two persisting endoleaks (a type-I 
and a type-III). A single patient required two revisions of a fem-fem crossover due 
to a graft infection.
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Table 3. Secondary interventions.
AUI, Aortic-Uni-Iliac graft
PTA, Percutaneous Transluminal Angioplasty
BMS, Bare Metal Stent
Figure 1. Kaplan-Meier curve representing the ten-year freedom from secondary procedures.
29Ten-year folow-up after endovascular abdominal aortic aneurysm repair 
Survival
The overall survival is presented is presented in fi gure 2. There was a median 
overall survival of 74.2 months. A total of 89 patients (61.4%) died within 10-years. 
The 1, 5 and 10-year survival rates were 88.3%, 55.2% and 38.6%, respectively. 
During follow-up three (2.9%) late aneurysm-related deaths occurred in the 140 
patients with a stent graft after 30-days. Two deaths were the result of a rupture 
and one patient died after excessive perioperative blood loss during a secondary 
intervention. 
Figure 2. Kaplan-Meier curves representing the ten-year freedom from all-cause mortality.
Survivors vs. non-survivors
A total of 56 patients (38.6%) were alive after 10-years (“Survivors”). Age, 
hypertension, cardiac risk and an American Society of Anaesthesiologists (ASA) 
classifi cation were signifi cantly different between survivors and non-survivors. In 
a multivariate regression analysis an ASA classifi cation of three or higher (hazard 
ratio (HR) 9.9; 95% confi dence interval (CI) 3.2-30.7), age (HR 1.1; 95% CI 1.0-1.2) and 
hypertension (HR 2.7; 95% CI 1.1-6.5) showed to have a signifi cant infl uence on 10-
year mortality. No difference in the number of secondary interventions between 
survivors and non-survivors were recorded (19.6% vs. 21.3%, p = .080).
30 Chapter 2
Discussion
Current guidelines advise lifelong surveillance after EVAR due to the high rate 
of late complications.7 Previously published reports often describe the 10-year 
experience and estimated outcomes. Our paper describes the long-term outcome 
of a widely applied stent graft more accurately, and gives insight in the distribution 
of complications.
The occurrence of graft and aneurysm related complications are the main 
downside of EVAR. In our population, the 30-day, 1, 5 and 10-year clinical success 
rates were 81.1%, 75.0%, 70.2% and 65.5% respectively. This result is difficult to 
compare because many publications use a variety of definitions for clinical 
success opposed to reporting standards of Chaikof et al..4 Although a clinical 
success rate clearly describes deviations from ideal treatment, it does not reflect 
the impact of these deviations. In this study, the initial clinical success is largely 
influenced by the existence of type-I or III endoleaks at completion angiography. 
The relevance of in particular small type-I endoleaks is widely debated. It has 
been shown that these endoleaks may seal spontaneously, similar to our results.8, 
9 Although, the initial clinical success is highly influenced by endoleaks of limited 
clinical relevance, the success rate does decline steadily during 10-years of follow-
up. This decline indicates that new complications occur throughout the complete 
follow-up period, however the rate is rapidly reduced after one year.
In total, 20.0% (30/145) of patients required at least one secondary intervention 
during a minimum of 10-year follow-up. The secondary intervention rates and 
indications reported in this study are comparable with previous reports.9, 10 The 
physiological impact of the interventions is limited, 64.9% could be resolved 
endovascularly and in 16.2% of cases a laparotomy was required. The secondary 
interventions were performed during the complete 10-year period. Although the 
rate of secondary interventions seems to stabilize after 1-year of follow-up, 20.7% 
of the initial secondary interventions were performed after five years (Figure 2). In 
70% of secondary interventions, patients did not experience any complaints, which 
is an important factor. Our data consequently show EVAR-related complications 
occur during the entire follow-up period. Regular follow-up imaging is required, 
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as the majority of complications do not cause symptoms. However, the follow-up 
schedule must be organized efficiently. 
Lifelong follow-up requires a great investment of time and resources, especially 
considering that 80% of patients require no secondary intervention. Guidelines 
propose a CTA at 30-days, 6-months and 1-year. The CTA at 6-months could be 
omitted if 30-day results are satisfying. It also states that a duplex ultrasound in 
combination with plain radiographs should be performed yearly after 1-year.7 The 
development of EVAR results in a better treatment outcome, and a decline in the 
need for secondary interventions.6 The follow-up strategy might be adjusted to 
better comply with current needs. In this study, no device integrity failures were 
recorded and four cases of graft migration without an endoleak. The value of plain 
radiographs in migration is questionable, aortic changes can mimic migration and 
not all changes are clinically relevant.11 Therefore, it is justifiable to only perform 
a duplex ultrasound in modern stent grafts.
Secondly, the timing of follow-up visits is important. As our results show the 
majority of complications arise in the first 5-years after implantation. The 
intensity of follow-up after five years could be reduced if patients experienced 
no adverse events. One possibility to design an efficient protocol is to allocate 
patients in risk groups based on baseline, perioperative and early follow-up 
data. Developments like the the “St George’s Vascular Institute (SGVI) risk score”, 
are essential to rationalize follow-up.12 The increasing quality of stent grafts, 
but also new approaches to EVAR like endovascular aneurysm sealing (EVAS) or 
polymer filled sealing rings, require reconsideration of follow-up strategies.13, 14 
In addition, aneurysm shrinkage is also associated with a reduced likelihood for 
secondary interventions.15 Therefore, a combination of data acquired pre-, peri- 
and postoperatively, is needed to compose a follow-up strategy that is safe, 
economical and acceptable for patients.   
The main benefit of EVAR is the low perioperative mortality. The DREAM and EVAR-
1 trials reported perioperative mortality for EVAR of 1.2% and 1.6%, respectively.2, 
3 This paper reports a perioperative mortality of 4.7% in patients treated in the 
same period as these landmark trials. Other series reporting on the Talent stent 
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graft reported a 30-day mortality of 1.1- 3.9%.9, 10, 16, 17 The variability of mortality 
rates might be explained by the EVAR-2 trial, which included patients not eligible 
for open repair based on comorbidities, and reported a perioperative mortality of 
9%.18 A closer analysis of our results showed that patients who died within 30-days 
were older and had more cardiac and renal disease than those who survived. As 
this study included all patients, fit or unfit for OR, the results resemble the current 
day-to-day practice. 
The short-term survival benefits of EVAR are not sustained in the long-term 
outcome. The overall long-term survival was 55.9% and 38.6% for 5 and 10-years, 
respectively. Other studies show an overall 5-year survival of 61% - 78% for 
endovascular treated AAAs.9, 10, 17, 19-21 Wibmer et al. reported a similar 10-year 
survival rate of 37.7%.19 A comparison of overall survival would be best performed 
in a RCT with patients that are suitable for both OR and EVAR. The best available 
evidence from DREAM and EVAR-1 suggests that the type of surgery does not 
influence overall long-term survival.22, 23 Similar secondary intervention rate for 
OR and EVAR in young patiënts have been reported. However, there is a significant 
difference in the indication where OR shows more wound related problems as 
opposed to graft related problems in EVAR.24 Factors that do predict long-term 
survival are age and comorbidities.10, 25 Therefore, OR should always be considered 
in young and healthy patients.
The indication for secondary interventions after EVAR suggests an increased risk 
of aneurysm rupture, and subsequently aneurysm related mortality. In this cohort 
the total aneurysm related mortality was 7.3%, the late aneurysm-related mortality 
was 2.9% (3/140). These rates are not significantly different from other studies with 
a follow-up of at least 5-years.9, 26, 27 Caution is advised when interpreting these 
results, as post-mortem examination is not common practice in the Netherlands 
and aneurysm related death could be underestimated.
The retrospective nature of this paper brings forth several limitations. The database 
was not designed to identify factors influencing clinical success and survival. 
The reported population cannot be compared to an open repair population, a 
number of patients were not eligible for OR. The cohort therefore, does provide a 
33Ten-year folow-up after endovascular abdominal aortic aneurysm repair 
real-world population that resembles current EVAR oriented era population. This 
study reports on a single type of stent graft making the data, regarding technical 
outcome, not transferable to other stent grafts. 
Conclusion
The risk of EVAR related complication is the highest in the first 5-years. The 
main focus must be on that period, further follow-up must not be neglected as 
complications occur up to 10-years after treatment.
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Abstract
Purpose: This study evaluates the differences in technical outcomes and 
secondary interventions between elective-EVAR (E-EVAR) and ruptured-EVAR 
(R-EVAR) procedures.
Methods: All primary EVAR cases for infrarenal aortic and aorto-iliac aneurysms 
conducted in our hospital from January 1998 until July 2012 were included. The 
E-EVAR group consisted of patients with asymptomatic and symptomatic AAA. The 
primary study endpoint was technical success. Secondary endpoints included 
freedom from secondary interventions and late survival.
Results: Among the 863 patients admitted in the current study, the E-EVAR group 
included 773 (89,6%) patients and the R-EVAR group included 90 (10.4%) patients. 
At baseline, R-EVAR patients had larger aneurysms on average (p < .001) compared 
to E-EVAR patients. Operation technical success was comparable (p = .052), but 
there were more type IA endoleaks at completion angiography in R-EVAR (p = 
.038). As anticipated more patients died in the first month in the R-EVAR group 
compared to the E-EVAR group  (18.9% vs. 2.2%, p < .001).  At five-year, there was 
an overall survival of 65.1% for E-EVAR and 48.1% for R-EVAR (p < .001). Five-year 
freedom form type I/III endoleaks was significantly lower for R-EVAR compared to 
E-EVAR (78.7% vs. 90.0%, p = .003). Five-year secondary intervention free survival 
was not significantly different (E-EVAR 84.2% vs. R-EVAR 78.2%, p = .064). 
Conclusion: Within our cohort of primary EVAR patients, R-EVAR cases showed 
comparable stent-graft related technical outcome in both short and long-term. 
There is a higher incidence of Type IA endoleaks in the R-EVAR group, but not all 
Type IA endoleaks required a secondary intervention 
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Introduction
Endovascular aneurysm repair (EVAR) has become the preferred treatment of 
elective and ruptured abdominal aortic aneurysms (AAAs). The endovascular 
approach of AAAs is less invasive compared to open surgical repair (OR) and 
demonstrates decreased early mortality and morbidity.1,2 EVAR is however 
associated with increased rates of endograft-related complications, requiring 
more extensive follow-up and secondary interventions.3
The technical success of EVAR is dependent on accurate preoperative planning 
including aneurysm measurements and adequate endograft selection. In 
patients presenting with a ruptured AAA (RAAA), planning has to be done under 
pressure and in a limited time frame. Usually, there is no time for extensive image 
reconstructions with a dedicated measuring programme. In addition, the endograft 
will be selected from the limited available stock. Due to the nature of RAAAs it 
is reasonable to assume that the interventionist will speed up the procedure to 
reach adequate haemostasis. All these factors can influence the procedure and 
this can hypothetically have an effect on the safety, durability and effectiveness 
of the endograft in both short and long-term outcome. 
This study was performed to describe the short and long-term outcome of EVAR in 
a consecutive cohort of patients treated in a high-volume centre, and to evaluate 
the differences between elective EVAR (E-EVAR) and ruptured EVAR (R-EVAR).
Methods
Patient population
In this study we used our hospital database for a retrospective analysis. The 
Catharina Hospital is a high-volume and tertiary centre for vascular surgery. Being 
one of the first centres in the Netherlands performing EVAR, our vascular unit 
gained a long experience and is considered a referral hospital for complex AAA 
cases. Since the first EVAR procedure was performed in our clinic in 1995, patients 
were prospectively enrolled in a database and follow-up was conducted. For this 
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study we selected only primary EVAR procedures conducted in our hospital from 
September 1998 until July 2012, in patients with aneurysms of the infrarenal aorta 
and iliac arteries. Patients primarily treated in other hospitals or treated with OR 
were left out of this analysis. Patients who were treated with the first generation 
of endovascular stent grafts, which were held off-market quickly, were excluded 
for this analysis (mainly before 1998). 
Follow-up for all patients was completed as up to February 2013, by intensive 
patient file reviewing and by consulting the national mortality registry. Whenever 
follow-up data was missing, we contacted general practitioners and local hospitals, 
and requested for insight in patient records.
Definitions and outcomes
For this study we divided our cohort of patients in two groups: E-EVAR and 
R-EVAR. Patients were assigned into the R-EVAR group if blood outside the aortic 
wall was present on computed tomography angiography (CTA). The E-EVAR group 
included patients with asymptomatic and symptomatic AAAs. In our experience, 
the management of symptomatic AAAs is comparable with asymptomatic AAAs; 
specifically there was reasonable time to perform adequate procedure planning. A 
variety of endografts were used, including AneuRx, Talent and Endurant (Medtronic, 
Santa Rosa, California, USA), Excluder (W.L. Gore and Assoc, Flagstaff, Arizona, USA), 
Zenith (Cook, Bloomington, USA), Endologix (Endologix PowerLink System, Irvine, 
USA), LifePath (Edwards Lifesciences LLC, Irvine, USA) and Fortron (Cordis Corp./
Johnson & Johnson Inc, Miami Lakes, USA). The selection for a particular type 
of stent graft was at the surgeon’s discretion and based on device’s availability. 
Postoperative follow-up included clinical examination at discharge and imaging 
at 1, 6 and 12 months, and yearly thereafter. 
The primary endpoint is the initial technical success. Technical success was defined 
as successful delivery and deployment of the endograft, without unintentional 
coverage of renal arteries, internal iliac arteries or visceral branches, with 
absence of either a type I or type III endoleak, followed by successful removal of 
the delivery system.4 The secondary endpoints are represented by the evaluation 
of early and late outcomes through analysis of perioperative mortality, overall 
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survival, incidence of late complications, need for secondary procedures and the 
freedom from these. We analysed the perioperative mortality defined as mortality 
from any cause occurring within 30 days of surgery. Aneurysm-related mortality 
included all deaths due to aneurysm rupture, a primary or secondary procedure, 
or surgical conversion. A secondary procedure was defined as an endovascular or 
open surgical intervention performed after the initial EVAR in order to maintain the 
function or patency of the endograft and to treat the most common complications 
of EVAR procedures: endoleaks, endograft migration and graft limb stenosis/
occlusion. Endograft obstruction included endograft related occlusion, stenosis, 
kinking and migration. Device migration after EVAR is endograft movement of >10 
mm relative to anatomic landmarks on CTA or any migration causing symptoms or 
requiring intervention.5 
Statistical analysis
Categorical variables are presented as frequencies with percentages. The χ2 
test or Fisher’s exact test was used to test significance for categorical variables 
according to sample size. Continuous variables are presented as mean ± standard 
deviation (SD) or as median and interquartile range (IQR) in case of skewed data. 
The independent group t-test was used to test significance in mean differences 
and the Mann-Whitney U test for median differences. Kaplan-Meier curves and 
log-rank tests were used to evaluate survival. Patients eventually not treated 
with EVAR were excluded for follow-up analysis. A p-value < .05 was considered 
statistically significant. All statistical analyses were performed using SPSS version 
21 for MAC (IBM Corporation, Armonk, NY, USA).
Results
From September 1995 until July 2012, 907 patients were treated with primary EVAR 
in our clinic. The first R-EVAR patient was treated in March 1999. A total of 43 cases 
were excluded because a first generation device was implanted: 14 with Stentor 
(MinTec La Ciotat, France) and 29 with Vanguard (Boston Scientific Corporation, 
Natick, MA). Among the remaining 863 patients, the E-EVAR group included 773 
(89.6%) patients and the R-EVAR group included 90 (10.4%) patients. 
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Baseline characteristics
Patients’ demographics and risk factors (Table 1) were typical for an AAA population, 
with a high prevalence of cardiovascular risk factors and co-morbidities. Patients 
were predominantly male. The mean age was 72.2 ± 7.7 years for E-EVAR and 73.4 
± 8.5 years for R-EVAR (p = .189). Mean maximum AAA diameter was signifi cantly 
smaller for E-EVAR compared to R-EVAR (E-EVAR 59 ± 12 mm vs. R-EVAR 70 ± 18 mm, 
p < .001).
Intra-operative results
Table 2 describes the variety of endografts used. The most commonly used 
endograft was the Talent (E-EVAR: 30.8%; R-EVAR: 63.3%) in both groups. A bifurcated 
endograft confi guration was more frequently used in E-EVAR than R-EVAR (90.9% 
vs. 45.6%, p < .001). Initial procedural data and evaluation are detailed in Table 3. 
a Values are reported as mean ± standard deviation or as frequencies (%) (n). 
b Abdominal aortic aneurysm
Table 1. Patient demographics and risk factors stratifi ed by operative indication.
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a Values are reported as frequencies (%) (n). 
b Aorto-uni-iliac
a Values are reported as median with interquartile range or as frequencies (%) (n). 
Denominator differs when there are missing values.
b Completion angiography was available in 757 E-EVAR patients and 87 R-EVAR 
patients.
Table 2. Endograft used for EVAR stratifi ed by operative indication.
Table 3. Initial procedural data and evaluation stratifi ed by operative indication.
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The median procedural duration was 120 (IQR: 90 – 150) min in E-EVAR and 135 
(IQR: 101 – 180) min in R-EVAR (p = .002). Technical success was obtained in 95.0% of 
elective and 90.0% of ruptured cases (p = .052). There was no significant difference 
in conversion to open surgery (E-EVAR 1.6% vs. R-EVAR 2.2%, p = .650). There were 
no intra-operative deaths recorded. 
Intra-operative endoleaks
The presence of a type IA endoleak at final angiogram was significantly higher 
for R-EVAR (6.9% vs. 2.8%, p = .038). Within 30 days, 16 type IA endoleaks resolved 
without any secondary intervention and one type IA endoleak resolved with 
placement of proximal extension. Three type IA endoleaks were persistent. All 
(6/6) type IA endoleaks at completion angiography in the R-EVAR group resolved 
without intervention. One type IB in the E-EVAR group endoleak was excluded with 
a distal extension. The two type III endoleaks in the E-EVAR group both resolved 
without intervention.
Thirty-day outcomes and complications
A total of 757 E-EVAR and 83 R-EVAR eventually underwent EVAR and were evaluated 
for 30-day outcome (Table 4). Median hospital stay was 3 days (IQR: 2–5) for E-EVAR 
and 9 days (IQR: 5–14) for R-EVAR (p < .001). From operation to hospital discharge, 
systemic complications (cardiac, pulmonary, cerebral, renal, bowel, and sepsis) 
were observed in 5.3% E-EVAR versus 25.6% R-EVAR patients (p < .001). Significantly 
more patients died in the first month in the R-EVAR group (18.9% vs. 2.2%, p < .001).
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There were signifi cantly more type I endoleaks reported in the R-EVAR group (E-EVAR 
1.0% vs. R-EVAR 4.5%, p = .014) within the fi rst 30 days. Among these endoleaks, three 
type I endoleaks in the E-EVAR group were also present at completion angiography. 
There was no difference in the incidence of type III endoleaks. Nine (1.2%) E-EVAR 
patients versus three (3.4%) R-EVAR patients underwent a secondary endovascular 
procedure in the fi rst month, mainly to resolve endoleaks and occlusions of the 
endograft. Three patients underwent extra-anatomic bypass surgery to resolve 
progressive limb occlusion, all in the E-EVAR group. Within the fi rst 30 days, three 
cases were converted to open surgery, all in the R-EVAR group. One patient had 
removal of an infected endograft. Another conversion was necessary because the 
endograft was blocking both renal arteries. The third patient was converted to 
open surgery because of a persistent type IA endoleak. 
Late outcomes and complications
Median follow-up was 37.8 (IQR: 16.6-77.7) months for E-EVAR and 21.0 (IQR: 2.8-
65.2) months for R-EVAR. Freedom from secondary procedures after 5 years was 
84.2% for E-EVAR and 78.2% for R-EVAR (p = .064, Figure 1). 
a Only implanted patients were analysed. Values are reported as median with 
interquartile range or as frequencies (%) (n/N). Denominator differs when there are 
missing values.
b Including three type I endoleaks seen at completion angiography during index 
procedure.
Table 4. Hospitalisation and complications within 30 days stratifi ed by operative indication
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Figure 2 represents the freedom from type I/III endoleaks showing a signifi cant 
lower rate of freedom from endoleaks in the R-EVAR group after 5-year follow-up 
(E-EVAR 90.0% vs. R-EVAR 78.7%, p = .003). A total of 63 E-EVAR patients developed 
a type I/III endoleak, of which 32 were corrected with a secondary intervention, 
28 resolved spontanously, and 4 were accepted and persisted during follow-up. 
There were 14 type I/III endoleak in the R-EVAR group, of which 9 were corrected 
with a secondary intervention and the remaining 5 resolved spontaneously.
Figure 1. Kaplan-Meier curves representing the fi ve-year freedom from secondary procedures in 773 
E-EVAR and 90 R-EVAR patients. Log rank, p = .064.
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After 5 years of follow-up, there was no signifi cant difference in freedom for 
endograft obstruction between groups (E-EVAR 91.9% vs. R-EVAR 87.0%, p = .073, 
Figure 3). The survival rates for all cause mortality after 5-year were 65.2% for 
E-EVAR and 48.1% for R-EVAR (p < .001) and freedom from AAA-related mortality 
was 95.7% for E-EVAR and 71.0% for R-EVAR (p < .001, Figure 4).
Figure 2. Kaplan-Meier curves representing the fi ve-year freedom from type I/III endoleaks in 773 
E-EVAR and 90 R-EVAR patients. Log rank, p = .003.
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Figure 3. Kaplan-Meier curves representing the fi ve-year freedom from endograft obstruction 
including: occlusion, stenosis, kinking and migration in 773 E-EVAR and 90 R-EVAR patients. Log-rank, 
p = .073.
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Figure 4. Kaplan-Meier curves representing the fi ve-year freedom from all-cause and AAA related 
mortality in 773 E-EVAR and 90 R-EVAR patients. Log-rank, all-cause mortality: p < .001, AAA-related 
mortality: p < .001.
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Discussion
Our 15-year single-centre experience shows that endovascular repair of elective 
and ruptured AAAs is a safe and feasible technique. Major differences comprised 
a higher overall mortality rate and a higher incidence of type I endoleaks in the 
R-EVAR group after 30-day and a higher incidence of type I/III endoleaks after 
five-year follow-up.
Since the first report in 1994 by Yusuf et al., the endovascular approach for RAAAs has 
been applied with increasing frequency.6,7 To improve the outcome and to ensure 
high quality R-EVAR care, Mehta et al. suggested a standardized multidisciplinary 
protocol. This protocol included the presence of an experienced staff consisting of 
vascular surgeons, anaesthesiologists, emergency room physicians and operating 
room personnel. The vascular surgeon must have a dedicated operating room 
and a sufficient stock of off-the shelf endografts at his disposal.8 Following such 
a protocol, anatomically suitable RAAAs are now primarily treated with EVAR with 
better outcome.9-11
A theoretical reduction in technical success for R-EVAR could be explained 
by limited endograft availability, the need for rapid assessment of aneurysm 
morphology and swift endograft deployment. However, this study demonstrates 
excellent technical success rates of EVAR in both elective and emergency settings 
(95% and 90%, respectively). The need for conversion to open surgery was low in 
both groups and there were no intra-operative deaths reported. However, we did 
find a significant difference in the appearance of type IA endoleaks at completion 
angiogram between the two groups in favour of elective treated patients. Because 
of an increased risk of AAA rupture, aggressive management of intraoperative 
type IA endoleaks is recommended.12 If adjunctive intraoperative endovascular 
procedures are unsuccessful, only small type IA endoleaks in already stabilized 
RAAA patients can be accepted. In the first month, the majority of these type IA 
endoleaks resolved spontaneously without the need of a secondary procedure. 
The disappearance of type IA endoleaks after appropriate endograft sizing may 
result from improved graft-wall apposition and thrombosis of low-flow type IA 
endoleaks.13 Extensive image surveillance is advised in these patients, because 
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high recurrence rates after spontaneous sealing of type IA have been reported.14,15
Several studies have demonstrated that the Achilles’s heel of EVAR is the high 
rate of secondary interventions after an initial advantage in terms of survival. The 
majority of secondary interventions in EVAR are performed to resolve endograft 
migration and type I and III endoleaks, which are independent risk factor for AAA 
rupture after EVAR. All delayed type I and III endoleaks should be treated because 
of a high risk for rupture.5,16 
Despite significantly more Type I endoleaks in the R-EVAR group, our single-centre 
experience shows no significant differences in the need for endograft related 
secondary interventions between elective and emergency AAA repair at five-
year. We also found that a large part of endoleaks resolved spontaneously. The 
anatomical fit between aortic anatomy and the stent graft could be considered 
as predictive factors for re-intervention.17,18 Therefore, accurate sizing is essential 
to select the most suitable endograft. This study also shows that swift anatomical 
assessment and the availability of a limited stock of endografts do not influence 
the outcome. In specialized vascular centres, the limited time seems to be 
sufficient to perform CTA imaging and to assess EVAR suitability in patients with a 
RAAA without increasing the mortality.19 
We included a variety of endografts for this study and the risk for endograft 
related complications is considerably higher in patients treated with early 
generation stent grafts.20,21 For this reason we have excluded all patients treated 
with first generation endografts (Stentor and Vanguard). The evolution of 
endograft technology has resulted in a multitude of endograft configurations 
with modular components and lower profile delivery systems, which allows 
treatments of patients who may have been excluded previously. Partly due to 
these developments in EVAR, the complexity of aneurysms treated with EVAR has 
also increased over time. 
In the early years of emergency EVAR, there was no consensus on whether 
to use bifurcated or aorto-uni-iliac (AUI) devices for the management of 
RAAAs. Some interventionists prefer the use of AUI devices because there is 
52 Chapter 3
no need for cannulation of the contralateral limb, which may result in faster 
haemorrhage control.22 However, a major disadvantage of AUIs remains the need 
for a femorofemoral crossover bypass to vascularize the contralateral leg. This 
results in longer operating times and a higher risk of graft infection and graft 
thrombosis. In contrast to AUI devices, emergency EVAR with bifurcated devices 
can be performed under local anaesthesia.23 We reported a more frequent use of 
AUI devices for the treatment of RAAAs. This could be explained by the limited 
availability of bifurcated grafts in the early years of R-EVAR.24 In the last decade, 
with an increased stock of endografts, we prefer the use of bifurcated devices for 
the treatment of RAAAs. 
Study limitations
The majority of data were collected prospectively and analysed retrospectively. 
Selection criteria for endovascular treatment have evolved during the inclusion 
period. This results in more challenging aortic morphologies treated in the more 
recent cases. 
Conclusion
EVAR appears technically comparable in patients with non-ruptured and ruptured 
AAAs. Swift anatomical assessment and the availability of a limited stock of 
endografts do not influence the technical success and secondary intervention 
rate of EVAR.
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Abstract
Purpose: This study examined outcomes of endovascular aortic aneurysm repair 
(EVAR) using general, regional or local anesthesia. 
Methods: From March 2009 to April 2011, patients were enrolled from 79 sites 
in 30 countries worldwide and treated with an Endurant Stent Graft System 
(Medtronic, Santa Rosa, CA, USA). Data were compared among three groups based 
on anesthesia type used. Multivariate logistic regression analysis was performed 
to adjust for possible confounding factors.
Results: General anesthesia (GA) was used in 785 patients (62%), regional anesthesia 
(RA) in 331 patients (27%), and 145 patients (11%) received local anesthesia (LA). 
There were intercontinental differences in the distribution of type of anesthesia 
used for EVAR. Higher ASA classification was associated with predominant use of 
GA. Procedure time was reduced in LA (80.4 ± 40.0 min) compared with RA (94.2 
± 41.6 min, adjusted P = .001) and GA (105.3   46.0 min, adjusted P < .001). ICU 
admission was less frequent for RA than for GA (adjusted OR 0.71, 95% CI 0.53 
– 0.97) and LA (adjusted OR 0.51, 95% CI 0.33 – 0.79). Postoperative hospital stay 
was significantly shorter for RA and LA compared to GA (adjusted P = .003 resp. 
adjusted P = .100). There were no significant differences in systemic and surgical 
complications. Mortality rates within 30-days did not differ between the groups. 
Conclusions: Type of anesthesia used during EVAR has no influence on perioperative 
mortality and morbidity. The use of local or regional anesthesia during EVAR 
appeared to be beneficial concerning procedure time, ICU admission and post-
operative hospital stay. 
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Introduction
Since the introduction of endovascular aortic repair (EVAR) in 1991, there have been 
substantial changes in the treatment of abdominal aortic aneurysms (AAAs).1 With 
improved delivery technique and better technical features of the next generation 
stent grafts, EVAR shows lower intra-operative mortality and morbidity compared 
with the conventional open operation of AAA.2-4
After 20 years, there is still no consensus about which type of anesthesia is most 
suitable for EVAR. Feasibility of local and regional anesthesia was proven in 
1999.5 According to the guidelines of the European society of vascular surgery, 
the preferential use of local anesthesia for EVAR is feasible and appears to be 
well tolerated, restricting regional anesthesia or general anesthesia only to those 
with predefined contraindications.6 The Society for Vascular Surgery practice 
guidelines suggests the use of epidural and local anesthetic along with conscious 
sedation for patients undergoing EVAR.7 However, these guidelines are based on a 
low level of evidence and recommendation. 
The main objective of this study was to compare different anesthesia techniques 
in a real-world setting. We used data from the prospective Endurant Stent Graft 
Natural Selection global Post-market Registry (ENGAGE) database for retrospective 
analysis. 
Methods
Patients and database
Data from 1263 prospectively enrolled patients enrolled in the ENGAGE Registry 
were used for this analysis. The ENGAGE Registry was undertaken to quantify 
the performance of the Endurant Stent Graft System (Medtronic, Santa Rosa, CA, 
USA) within the context of contemporary, real-world use. The ENGAGE Registry 
is a multi-center, non-randomized, prospective observational study. The trial 
was conducted according to the Declaration of Helsinki and the International 
Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines, and 
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approved by local medical ethics committees. Ruptured AAAs were not considered 
for enrolment into ENGAGE. Stokmans et al. described full methodological details 
of the ENGAGE Registry in an earlier publication.8 
Definitions and outcome variables
From the database we retrospectively selected three groups based on anesthesia 
type used during operation: local, regional and general anesthesia. Local 
anesthesia was defined as infiltration of local anesthetics into the groin whether or 
not in combination with sedation. Spinal anesthesia and epidural anesthesia were 
both defined as regional anesthesia. If multiple anesthesia techniques were used, 
patients were categorized in the group of most invasive anesthetic technique. Data 
about type of anesthesia were derived from operation and anesthesia reports. A 
symptomatic AAA refers to any of a number of symptoms (e.g.: abdominal pain, 
back pain and limb ischemia) that can be attributed to the aneurysm. Pre-existing 
medical comorbidities and cardiovascular risk factors were recorded. Collection 
of this data has been described in a previous publication.9 
The primary outcome was perioperative success defined as 30-day morbidity and 
mortality. Secondary outcome measures for this analysis included procedural 
data, adverse events and quality of life.
Initial technical success was defined as successful delivery and deployment of 
the Endurant endograft, without unintentional coverage of renal arteries, internal 
iliac arteries or visceral branches, with absence of either a type I or III endoleak, 
followed by successful removal of the delivery system.10 Duration of implant 
procedure was defined as the time between cut down or puncture and removal 
of the last guide catheter. Fluoroscopic time, volume of contrast, post-operative 
stay and possible intensive care unit (ICU) admission were documented. Thirty-
day complications included all-cause mortality, cardiac complications, bowel 
ischemia, neurologic complications, renal failure, respiratory failure, and surgical 
complications. Thirty-day follow-up was completed for all patients.
Quality of life was assessed using the EuroQoL 5-Dimensions Questionnaire 
(EQ-5D) index score; a standardized instrument for use as a measure of health 
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outcome in three different ways.11 The descriptive system has five dimensions 
(mobility, self-care, usual activity, pain/discomfort, and anxiety/depression) and 
three levels (no problems, some problems, extreme problems), which create 243 
unique health states and can be converted into a single summary index (EQ-5D 
index) by applying scores from a set of general population preference weights. 
This study used the Dutch TTO value set to calculate the EQ-5D index. The third 
measure was a 0 to 100 visual analogue scale (VAS) for self-rating a patient’s own 
health. Ratings took place at the first contact (baseline), at discharge, and at the 
30-day outpatient visit.
Data collection and statistical analysis
Data collected were recorded on a web-based electronic case report form. 100% 
of the data were reviewed, and more than 40% of patients’ source documentation 
was monitored randomly.8 Each site’s Institutional Review Board approved data 
collection and analysis. Informed consent for authorization of data release was 
obtained in all patients.
Categorical variables are presented as frequencies with percentages. Continuous 
variables are presented as mean ± standard deviation or as median and interquartile 
range in case of skewed data. Differences in baseline characteristics among the 
three study groups were analyzed using the χ2 test for discrete variables and the 
ANOVA or the Kruskal-Wallis test for continuous variables. Multivariate logistic and 
linear regression analyses were used to adjust for possible confounding factors. 
Multicollinearity was checked using the variance inflation factor (VIF) and the 
tolerance. A P-value < 0.05 was considered statistically significant. However, we 
adjusted the P-value (P < 0.017) for multiple testing, because we performed three 
comparisons between groups in the regression analysis (Bonferroni correction). 
All statistical analyses were performed using SPSS® version 20 for MAC (SPSS, 
Chicago, Ill).
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Results
Among the 1263 consecutive patients enrolled in the ENGAGE registry, 145 (11.5%) 
had local anesthesia (LA), 331 (26.2%) had regional anesthesia (RA) and 785 (62.3%) 
had general anesthesia (GA). The GA group includes 6 patients who scored both 
spinal and general anesthesia. Two patients were excluded from the study due 
to lack of recording the anesthesia type. Data for the remaining 1261 patients 
comprise the basis of this report. Figure 1 shows the distribution of anesthesia 
type used in ENGAGE. There were intercontinental differences in the distribution 
of type of anesthesia used for EVAR. Also, differences between regions in Europe 
were reported. 
Baseline characteristics
Demographic data and baseline risk factors are presented in Table 1. On average, 
there was an overall signifi cant difference in age in GA, RA and LA patients, 
respectively with a mean age of 73.6 ± 8.1 years, 72.3 ± 8.1 years and 72.3 ± 7.7 
years (P = .026). Patients were predominantly men and the distribution of sexes 
was comparable between the groups. Distribution in different American Society of 
Anesthesiologists (ASA) class was not equal (P = .002). ASA class IV was associated 
with predominant use of GA (Figure 2). Symptomatic presentation was lower in LA 
and RA patients compared to GA patients (P = .004). Risk factors such as tobacco 
Figure 1. Distribution of anesthesia type by American Society of Anesthesiologists (ASA) classifi cation. 
GA, general anesthesia; LA, local anesthesia; RA, regional anesthesia.
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a Denominator differs when there are missing values. 
b American Society of Anaesthesiologists.
c Signifi cantly different
Table 1. Baseline characteristics according to anesthesia type
Figure 2. Distribution of anesthesia type by geographic region. GA, general anesthesia; RA, regional 
anesthesia; LA, local anesthesia.
use, hyperlipidemia, coronary artery disease and cardiac revascularization were 
overall signifi cantly different between groups. 
64 Chapter 4
Baseline aneurysm characteristics are summarized in Table 2. There were no 
signifi cant differences in AAA diameter (P = .449). Distal iliac fi xation site diameters, 
proximal non-aneurysmal neck length and angulation were signifi cantly different 
between groups.
a Abdominal aortic aneurysm 
b Signifi cantly different
Intra-operative outcome
Initial procedural data and evaluation are detailed in Table 3. The mean adjusted 
procedural duration was signifi cantly shorter in LA (80.4 ± 40.0 min) compared 
to RA (94.2 ± 41.6 min, adjusted P = .001) and GA (105.3 ± 46.0 min, adjusted P < 
.001). There were no signifi cant differences in type I and/or type III endoleaks 
at completion angiography between groups. Type of anesthesia used did not 
infl uence technical success rates. No intra-operative deaths occurred. Focusing 
on hospitalization, GA patients were signifi cantly longer in the hospital than RA 
and LA patients (adjusted P = .003 resp. adjusted P = .010). GA and LA patients were 
admitted more frequently to the ICU than RA patients (adjusted OR 1.40, 95% CI 
1.03 – 1.90 resp. adjusted OR 0.51, 95% CI 0.33 – 0.79).
Table 2. Baseline aneurysm characteristics.
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a Adjusted for: Age; Baseline symptoms; ASA classifi cation; Tobacco use; 
Hyperlipidemia; Coronary artery disease; Cardiac revascularization
b Odds ratio
c Intensive care unit
d Signifi cantly different (P < .017)
Table 3. Initial procedural data and evaluation by anesthesia type.
Mortality and morbidity
Thirty-day outcome is summarized in Table 4. Within 30 days after implant, 11 GA 
patients (1.4%) died versus 3 RA patients (0.9%, adjusted OR 1.42, 95% CI 0.38 - 
5.31) versus 2 LA patients (1.4%, adjusted OR 0.80, 95% CI 0.16 – 3.89). There were 
no signifi cant differences for systemic and surgical complications. 
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Activities of daily living and quality of life
Table 5 displays differences in quality of life data between groups at each of the 
three time points (intergroup differences) and within each group from preoperative 
baseline to discharge and 30 days (intragroup differences). At baseline, quality 
of life and the dimensions of health status were similar in the three groups. At 
discharge, the LA group scored signifi cantly better on usual activities and self-
care. The change in EQ-5D index from baseline to discharge was negative in GA 
and RA patients (-0.06 ± 0.22 and -0.03 ± 0.17, respectively), no change was found 
in LA patients (0.00 ± 0.19) (P = .006). After 30 days, there is an overall signifi cant 
difference in VAS-score between study groups (P = .021) favoring LA patients. 
Changes in EQ-5D index from baseline to 30 days follow-up are positive for all 
groups and overall not signifi cantly different (P = .328). 
a. Adjusted for: Age; Baseline symptoms; ASA classifi cation; Tobacco use; 
Hyperlipidemia; Coronary artery disease; Cardiac revascularization
b. Odds ratio
Table 4. Patient outcome within 30 days post implant by anesthesia type.
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a. Inter Quartile Range.
b. Dutch TTO value set used to calculate EQ-5D index score.
c. Signifi cantly different
Table 5. Outcome of activities of daily living and quality of life by anesthesia type.
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Discussion
The effect of different anesthetic techniques in EVAR is described in small studies 
with possible selection bias. Unprecedented in size, scope, and geographic 
representation, the ENGAGE Registry represents the collective experience of 79 
centers in 30 countries across five different continents with the Endurant Stent 
Graft. Patients with a wide spectrum of comorbidities were included, resulting in 
a representation of everyday real-world clinical practice.8 
According to the European and American guidelines, the use of local anesthesia for 
EVAR is preferred.6,7 Despite this consensus, EVAR is still mainly conducted under 
general anesthesia.12-15 A majority of the patients (62.3%) in our study were treated 
under GA. However, we found an existence of large intercontinental differences for 
the primary choice of anesthetic. The differences between regions in Europe were 
even more remarkable. This could be explained by sustained regional customs 
of vascular surgeons and anesthesiologists. Another interesting finding is that 
patients in the GA group had a significant higher ASA score, which is not according 
the European guidelines.6 Unfortunately, the registry does not foresee in a specific 
explanation on the individual choice of anesthesia. We can therefor only speculate 
on individual preferences.
Geisbüsch et al. concluded in a cohort of 217 continuous patients that with 
a ‘local anesthesia first strategy’, LA could be applied in approximately 75% of 
patients undergoing elective EVAR.16 Lachat et al. published their first results of 
100 consecutive patients treated percutaneously under local anesthesia in an 
outpatient setting, showing excellent results.17 We described a more frequently 
use of LA in our data compared to the EUROpean collaborators on Stent-graft 
Techniques for abdominal Aneurysm Repair (EUROSTAR) data (resp. 11.5% vs. 
5.6%).14 This could imply that nowadays more LA is applied. 
EUROSTAR data indicated no differences in surgical outcome between types of 
anesthesia.14 Our results are consistent with these findings, showing comparable 
rates of technical success and endoleaks between groups. In addition, we reported 
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no significant differences in the need for secondary procedures within 30 days 
after implant.
LA and RA reported shorter operation time and hospital stay than GA.12,14,18,19 In 
contrast to previous reports, we reported a remarkable higher requirement for ICU 
admission in the LA group.13,14,18-21 This difference might be caused by two centers 
that had 100% ICU admission in 38 LA patients (26.2%). When we excluded this 
group, we found a significant lower ICU admission for LA (22.4%) compared to GA 
(35.8%, adjusted OR 0.55, 95% CI 0.33 – 0.91). 
LA and RA are proven to be feasible and safe as an alternative for general 
anesthesia during EVAR.22 All-cause mortality rates were low in all three groups 
and were comparable with other studies.14,15 We reported no differences in short-
term complications. We did see a trend that LA resulted in fewer complications, 
however a significant advantage for LA was not established. This is probably due 
to the low incidence of complications and the infrequent use of LA. 
Bakker et al. described a significantly higher cardiac event rate at thirty days 
comparing general and locoregional anesthesia (OR 3.8, 95% CI 1.1-12.9).23 Despite 
a larger group of patients, we found no significant difference in cardiac event 
rates between general and locoregional anesthesia (OR 1.09, 95% CI 0.45 – 2.67).
The success of EVAR is highly dependent on patients’ AAA anatomy. Short and 
angulated infrarenal aortic necks increase the risk of type 1 endoleaks.24 Complex 
AAA anatomy may also extend the duration of surgery, resulting in more discomfort 
for patients treated with locoregional anesthesia.25 We found a shorter infrarenal 
neck length and a smaller iliac access diameter in the LA group. However, these 
differences were minimal and did not result in relevant differences in AAA 
complexity. LA may influence imaging quality because it is very dependent on 
patient movement and their ability of holding their breath during imaging.16 This 
could be an explanation why we found significantly more contrast use in the LA 
group. 
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GA might be preferred for extremely complex cases when there is a possibility 
of immediate conversion to open surgery. However, we found a low conversion 
rate of 0.3% in our study population. Furthermore, with an appropriate anesthetic 
team standby, conversion to GA is always possible. 
To our best knowledge, this is the first study on anesthesia type and the effect of 
quality of life after EVAR. LA scored best on EQ-5D compared to RA and GA. This 
may imply that patients recover quicker after LA. 
This study has several limitations. Unfortunately, pre-operative clarification 
regarding the choice of anesthesia type is missing. Information regarding possible 
anesthesia type conversion was not documented. Therefore, we were unable to 
perform an intention-to-treat analysis and selection bias may have affected our 
results. The technique of femoral/iliac access was not documented. Percutaneous 
EVAR influence the amount of blood loss, operating time and post-operative stay, 
possibly confounding results. Also, one has to take into account that the ENGAGE 
registry was not designed nor powered for this specific retrospective analysis, 
restraining our findings.
Conclusion
The main findings of this study were that LA and RA had advantages compared 
with GA regarding duration of procedure, post-operative stay. No effects of type of 
anesthesia on procedural success rates and perioperative mortality and morbidity 
were reported. Patients seem to recover quicker after LA. Based on our results, we 
advise a strategy based on preferential use of locoregional anesthesia for EVAR 
restricting GA only to those with predefined contraindications. 
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Abstract
Objective: A ruptured abdominal aortic aneurysm (RAAA) is associated with a 
high mortality rate. If cardiopulmonary resuscitation (CPR) is required prior to 
operative repair, mortality rates are said to approach 100%. Aim of this multicenter, 
retrospective study was to study outcome in RAAA patients who required CPR prior 
to a surgical (endovascular or open) repair (CPR group). RAAA patients who did not 
need CPR served as controls (non-CPR group).
Methods: Over a five-year time period, demographics, clinical characteristics and 
specifics of preoperative CPR if necessary were studied in all patients who were 
treated for a RAAA in three large, non-academic hospitals. 
Results: A total of 199 consecutive RAAA patients were available for analysis, 176 
patients were surgically treated. Thirteen of these 176 patients (7.4%) needed 
CPR, whereas 163 (92.6%) did not. A 38.5% (5/13) survival rate was observed in the 
CPR group. Thirty-day mortality was almost three times higher in the CPR group 
compared to the non-CPR group (resp. 61.5% vs. 22.7%, p = .005). Both CPR patients 
receiving EVAR survived. In contrast, survival in 11 CPR patients undergoing open 
RAAA repair was 27% (3/11, p = .128). A trend for higher Hardman index scores was 
found in CPR compared to non-CPR (p = .052). The 30-day mortality in patients 
with a 0, 1, 2 or 3 Hardman index was 16.1%, 31.0%, 37.9% and 33.3%, respectively 
(p = .093).
Conclusion: A RAAA requiring preoperative CPR is not necessarily a lethal 
combination. Patient selection must be tailored before surgery is denied.
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Introduction
Although healthcare has demonstrated substantial improvements over the past 
decades, mortality rates in populations with a ruptured abdominal aortic aneurysm 
(RAAA) remain invariably high. For instance, the estimated total mortality rate of 
a recent series of patients suffering from RAAAs was 81%.1 In case patients arrive 
alive in the hospital and undergo emergent surgery, up to half will subsequently 
die in the perioperative period.2-4
Surgical outcome of RAAA may possibly improve if selection criteria for intervention 
are optimized. Scoring systems combining clinical findings and biochemical 
results were introduced for RAAA patients as a means to predict survival. One 
of these tools is the Hardman index that uses a set of five parameters. Although 
easily applicable, additional factors may also determine outcome.2 To date, not 
a single scoring system allows for a proper preoperative selection of candidates 
who might optimally benefit from vascular surgery for RAAA. 
The necessity of preoperative cardiopulmonary resuscitation (CPR) reflects the 
dismal condition of a RAAA prior to an invasive procedure. Therefore, it is highly 
questionable whether RAAA patients requiring preoperative CPR should be 
offered surgical treatment at all. Previous publications on the matter show that 
after cardiac arrest there is a possibility of survival.5, 6 However, a slim body of low-
level literature are adamant that these patients are unlikely to survive.7-9 Senior 
authors of the present study have experienced that some patients may survive 
following the unfortunate combination of CPR prior to RAAA treatment. 
Aim of the study was to evaluate clinical outcome in RAAA patients who received 
CPR prior to surgery (CPR). RAAA patients who did not need CPR served as controls 
(non-CPR). We also studied whether the Hardman index was of prognostic value 
in these resuscitated RAAA patients.
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Methods
Patient population
Consecutive patients registered with a RAAA (Dutch administrative code: DBC 406) 
between February 2009 and January 2014 were identified from hospital records 
of three large, non-academic teaching hospitals in the Netherlands. Inclusion 
criteria were RAAA and treatment using either endovascular aortic repair (EVAR) 
or open repair (OR). A RAAA was defined as a typical event of sudden severe 
abdominal pain in a patient having an aneurysm of the abdominal aorta and the 
presence of blood outside the adventitia of an aneurysmal abdominal aortic wall 
as determined using ultrasound (US). A contrast enhanced computed tomography 
angiography (CTA) was performed, if possible, to confirm the diagnosis and to allow 
for a precise treatment plan. Patients were excluded / not eligible if evidence of a 
rupture was lacking during OR. This retrospective study was conducted according 
to the Declaration of Helsinki and approved by local medical ethics committees. 
Patient informed consent was not required because this retrospective study did 
not involve medical treatment. Patient data were stored anonymously.  
Patient data were collected through hospital, emergency department, and 
operation records. All patients were treated by or under the supervision of 
a consultant vascular surgeon. Type of operation (OR or EVAR) was left to the 
discretion of the surgeon. If the prognosis due to comorbidity was deemed 
exceedingly poor or if treatment options were limited, patients were managed 
conservatively following consultation in the presence of the patient and family. 
Definitions and outcomes
Two patient populations were compared, a CPR and a non-CPR group. 
Cardiopulmonary resuscitation was defined as the combination of artificial 
respiration and heart massage by the exertion of pressure on the chest for at least 
a five-minutes period prior to the decision to institute invasive vascular surgery 
in a RAAA patient. A five-minute minimum was used to preclude the chance that 
an inadequate bystander reaction on loss of consciousness was registered as CPR. 
Whether the indication to initiate CPR was correct (type of cardiac arrest, e.g. 
ventricular fibrillation) was not the aim of our study, since we studied outcome 
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after CPR (bystander, paramedic, in-hospital). We strived to answer the question 
whether CPR in itself was conditional for a surgeon to abstain from further action. 
The primary end-point was 30-day or in hospital mortality. 
The Hardman Index was chosen for risk assessment. This tool was selected 
because it is easy to use in an emergency room setting as opposed to other scoring 
systems. It converts the presence/absence of 5 factors including age (>76 years), 
serum creatinine (>190 μmol/L), hemoglobin (<5.6 mmol/L), loss of consciousness 
after arrival at the emergency department (ED) and electrocardiographic (ECG) 
signs of ischemia into a 0 to 5 point score.2 We calculated the Hardman Index only 
in treated RAAA patients with available information regarding all five factors to 
avoid underscoring. 
Statistical analysis
Statistical analyses were performed using SPSS version 21 for MAC (IBM 
Corporation, Armonk, NY, USA). Categorical variables are presented as frequencies 
with percentages. Continuous variables are presented as mean ± standard 
deviation or as median and interquartile range (IQR) in case of skewed data. The 
χ2 or Fisher’s exact test were used for categorical variables according to sample 
size. Incidence rates with 95% confidence intervals were determined. A P-value < 
0.05 was considered statistically significant. 
Results
A total of 199 consecutive RAAA patients were identified during the five-year 
period of interest. No surgical treatment was offered to 23 patients (11.6%). Seven 
of these received prolonged CPR (>30 minutes) during transportation and/or 
during their stay in the ED. However, these efforts were in vain and they did not 
regain cardiac output. Sixteen additional patients received palliation, a vascular 
intervention, as considered by the attending vascular surgeon, was no option. 
Subjective reasons to deny invasive treatment in these patients were severe co-
morbidity and unfavorable vascular anatomy in patients who were physically not 
suitable to undergo OR.
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In the remaining 176 patients (88.4%), a treatment strategy consisting of controlled 
hypotension, medication and intravenous fl uids followed by surgery was initiated. 
Temporary CPR prior to surgery was required in 13 patients (CPR group, 7.4%) 
whereas 163 patients did not (non-CPR group, 92.6%). There were no signifi cant 
age and gender differences between these two groups (Table 1). One hundred 
and three open procedures (58.5%) and 73 endovascular procedures (41.5%) were 
performed (Table 2).
a Values are reported as mean ± standard deviation, median [Inter Quartile Range], or 
as frequencies (%) (n/N). Denominator differs when there are missing values.
b Fisher’s exact test
Table 1. Baseline characteristics, Hardman index score, 30-day mortality.
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There were more open procedures in the CPR group (11/13, 84.6%) compared to 
the non-CPR group (92/163, 56.4%, p = .047). Table 3 depicts patient demographics 
and CPR characteristics including duration and adrenaline and atropine 
administration. The majority of patients were resuscitated in the hospital (10/13, 
76.9%). Median CPR duration was 20 (IQR 12.5 - 30) minutes. Table 3 also shows 
the lowest pH, highest lactate levels and intraoperative required blood products. 
OR, open aneurysm repair; EVAR, endovascular aneurysm repair
a Fisher’s exact test
Table 2. Outcome based on type of treatment.
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NR, not reported; F, female, M, male; ED, emergency department; OT, operating theatre; DNR, do not 
resuscitate.
Hardman Index
A full set of fi ve variables was obtained and analyzed in 111 of 176 operated patients 
(63.1%). Values of serum creatinine, loss of consciousness and ECG were missing 
in three (1.7%), seven (4.0%) and 63 (35.8%) of the patients, respectively. No risk 
factor was present in 31 patients whereas 42 patients had one, 29 patients had 
two, nine patients had three; no patient possessed more than three risk factors. 
Hardman Index values were comparable between EVAR and OR patients (p = .503). 
As expected, the CPR-group demonstrated a trend towards a higher Hardman 
index compared to non-CPR patients (p = .052).
Table 3. Overview of patient characteristics, pre-operative status and follow-up of patients in the 
CPR-group.
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Mortality
CPR patients had an almost three times higher 30-day mortality rate compared 
to non-CPR patients (CPR 8/13, 61.5% vs. non-CPR 37/163, 22.7%, p = .005). The fi ve 
surviving CPR patients were still alive, and lived independently, at the time of 
writing of this paper (March 2015) median 1631 days (IQR 735-2015, Table 3). Notably, 
thirty-day mortality was signifi cantly lower for EVAR compared to OR across the 
entire population (EVAR 16.4% vs. OR 32.0%, p = .019). Thirty-day mortality in the 
CPR group was zero in patients receiving EVAR (n = 2) compared to 73% in OR (8/11, 
p = .128). The overall mortality rates in groups with a 0, 1, 2 or 3 Hardman score 
were 16.1%, 31.0%, 37.9% and 33.3%, respectively (Table 4). There was a tendency  (p 
= .093) towards the presence of a higher Hardman index and mortality.
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Discussion
The ominous effect of cardiopulmonary resuscitation on survival in RAAA patients 
is hardly studied. Two studies reporting a 100% mortality rate in preoperatively 
resuscitated patients advocate that invasive treatment should be denied.7, 9 In 
contrast, a 67% and 72.8% 30-day mortality rates have been observed in patients 
with a RAAA requiring CPR.6, 10 To our knowledge, this is the first multicenter-study 
describing survivors after resuscitation prior to RAAA surgery. As expected, the 
present study shows a substantially higher mortality rate in resuscitated RAAA 
patients (CPR 61.5% vs. non-CPR 22.7%, p = .005). Conversely, the 38.5% survival 
rate in our CPR patients is not far removed from the 33% survival rate as reported 
by Crawford.10
The identification of people requiring out-of-hospital CPR is difficult if not 
impossible. As a consequence, timing and duration of CPR may not always be 
optimal.11 Although CPR might possibly be deemed unnecessary in retrospect by 
experts, a CPR notion prior to ED presentation may lead to a less objective and a 
less aggressive patient assessment, based on the premise that the combination 
CPR/ RAAA is always lethal. A recent report on palliated RAAA patients created 
a subgroup based on CPR indicating this as the main reason for palliation.12 In 
contrast, the current study demonstrates that 38.5% RAAA patient survived a 
period of CPR prior to surgery and should therefore be given a fair assessment. 
Several explanations for increased survival rates following preoperative CPR in 
an RAAA population may be forwarded. Overall, improvements in preoperative 
management have reduced RAAA mortality rates in the last two decades.1 A 
previous adage of aggressive fluid administration in a RAAA patient is replaced 
by the concept of permissive hypotension. In 1991, Crawford suggested that 
extensive volume resuscitation in RAAA promoted loss of whole blood and 
coagulation factors. In contrast, ‘permissive’ hypotension would reduce these 
losses thus increasing survival possibilities.10 This concept is widely accepted 
and integrated in contemporary guidelines.13 Systolic blood pressures between 
50 and 100 mmHg are considered optimal if tolerated.13 Survival is in part also 
determined by the experience of dedicated professionals. In the Netherlands, 
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well-trained paramedics provide pre-hospital care. The application of permissive 
hypotension by Dutch ambulance staff in a retrospective study demonstrated an 
81% adherence rate.14 These modifications in preoperative patient management 
possibly have led to a better outcome.
The second major paradigm shift influencing outcome in RAAA is related to the 
vascular technique. Most modern vascular surgeons would contend that EVAR is 
the treatment of choice in elective AAA surgery.15 With increased endovascular 
possibilities, experienced vascular centers have also adopted an ‘EVAR first 
approach’ for the treatment of RAAAs. In our study, not all three centers used an 
EVAR first approach at any time. However, an increase of endovascular repair over 
time was observed. Large efforts such as the IMPROVE and AJAX trial comparing 
EVAR to OR failed to demonstrate a beneficial effect of either technique on 
mortality rates.3, 4 However, centers that introduced an EVAR first approach for 
RAAA did report improved overall mortality rates.16, 17 The reduction in mortality is 
presumably related to reduced blood loss and less procedural time.4, 18 Moreover, 
emergency EVAR can be safely performed under local anesthesia in cooperative 
patients avoiding systemic cardiovascular depression associated with general 
anesthesia.19, 20 In our total population the 30-day mortality based on treatment 
alone was significantly lower for EVAR compared to OR, respectively 16.4% vs. 32.0% 
(p = .019). Of the treated patients, EVAR was performed in two patients requiring 
CPR (14.5%) and in 71 (42.9%) patients who did not. It is noteworthy that both CPR 
patients that underwent EVAR survived even though their parameters such as pH, 
lactate and lowest blood pressure were poor (table 3). Therefore, endovascular 
repair is a feasible therapy, also in highly unstable patients. A recent study 
supports the contention that hemodynamically unstable RAAA patients possibly 
benefit from EVAR compared to OR as reflected by 30-day mortality rates.21 
There are roughly two options in the management of hemodynamic unstable 
RAAA patients. Patients can be directly transported to the operating theatre to 
initiate OR, or they can undergo a CT scan allowing for a decision on EVAR or OR. 
When considering that aneurysm morphology is a predictor of mortality in EVAR 
and OR, a CTA is of the utmost importance in treatment selection.22 In specialized 
vascular centers, there is sufficient time to perform imaging and to assess EVAR 
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suitability.23 
Despite all of these considerations, RAAA mortality rates are exceedingly high. 
It is therefore important to study tools that allow for an improved selection of 
patients, preventing fruitless attempts and high costs. In the present study, 23 
RAAA patients (11.6%) did not receive invasive treatment (CPR n=7, non-CPR n=16). 
These patients were deemed inoperable or were deceased before surgery could 
be initiated. A turn down rate of 11.6% is low in comparison to previously reported 
rates of up to 40%.24 Comparisons in RAAA care between the US and UK shows a 
very different palliation rate although treatment mortality rates are comparable.24 
Although there is no obvious explanation for this difference, the results do 
underline the difficulty in selecting patients who benefit from surgical repair.  
Various scoring systems to objectively identify high risk patients have been 
forwarded including the Glasgow Aneurysm Score (GAS), the Vascular- 
Physiological and Operative Severity Score for enUmeration of Mortality and 
Morbidity (V-POSSUM), Vancouver scorings system and the Hardman Index.2, 25-27 
The Hardman Index is a five-parameter tool that does not require calculations or 
knowledge of the patient’s medical history and is therefore highly suitable in an 
emergency setting. It was previously found that mortality rates were 16%, 37%, 
72% and 100% in populations with a score of 0, 1, 2 or 3, respectively.2 Because 
the Hardman index is reasonably blunt, it is less capable of identifying individual 
high-risk patient.28, 29 In the present study, the Hardman index was not a priori 
determined as a tool to preoperatively identify high-risk patients. After selection 
by the attending surgeon, the 30-day mortality rates of the entire population were 
16.1%, 31.0%, 37.9% and 33.3% for a Hardman Index of respectively 0, 1, 2 and 3. These 
percentages indicate that experienced vascular surgeons are capable of selecting 
patients, even from a group regarded as high-risk patients. Therefore, a surgeon’s 
experience and judgment should always outweigh a tool like the Hardman Index. 
In addition, an article by Cho et. al showed that CPR is not associated with an 
increased mortality rate.5 This underlines that tools like the Hardman Index and 
the notion of CPR should not be referred to as a reason for palliation, individual 
assessment is vital.
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Study limitations
The present study is a retrospective analysis with a limited sample size and 
therefore has its shortcomings. An unknown number of RAAA patients may have 
died before being correctly diagnosed so registration is possibly incomplete. 
Due to the urgent nature of a RAAA, documentation is sometimes limited. As a 
consequence, a substantial percentage of Hardman parameters are missing 
(36.9%). The conclusions should be interpreted with caution due to the limited 
sample size. Nevertheless, these limitations do not affect the finding of the present 
study that a group of patients survived the combination of CPR and treatment for 
a RAAA as opposed to previous beliefs.
Conclusion
Patients with RAAAs who respond to CPR prior to emergency repair do have a 
chance of survival. Although CPR and a high Hardman Index are associated with 
a poor outcome, both parameters should not be used as an absolute criterion to 
deny surgical intervention in a patient with a RAAA.
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Abstract
Objectives: To compare the midterm results of endovascular aortic aneurysm 
repair (EVAR) for ruptured abdominal aortic aneurysms (RAAAs) in patients with 
favourable aortic neck anatomy (FNA) and hostile aortic neck anatomy (HNA).
Methods: Patients treated for a RAAA in a high-volume endovascular centre in 
the Netherlands between February 2009 and January 2014 were retrospectively 
identified and divided into two groups based on aortic neck anatomy, FNA and 
HNA. HNA was defined as RAAA with a proximal neck of <10 mm, or a proximal 
neck of 10 - 15 mm with a suprarenal angulation (α) >45° and/or an infrarenal 
angulation (β) >60°, or a proximal neck of >15 mm combined with α >60° and/or 
β >75°. Patient demographics, procedure details, 30-day and one-year outcomes 
were recorded.
Results: Of 39 included patients, 17 (44%) had HNA. Technical success was 100% 
for FNA and 88% for HNA (p = .184). There were no type IA endoleaks at completion 
angiography in either group, however more adjunctive procedures were necessary 
for intraoperative type IA endoleaks in the HNA group (24% vs. 0%, p = .029). Thirty-
day mortality rates were comparable, FNA 14% vs. HNA 12%, p = 1.000. There were 
no statistically significant differences at one-year follow up in type I endoleaks, 
secondary endovascular procedures, and all-cause mortality.
Conclusions: In our experience, emergency EVAR provided excellent results for the 
treatment of RAAA patients with both FNA and HNA. EVAR in RAAAs with HNA is 
technically feasible and safe in experienced endovascular centres. 
anatomy is technically feasible and safe in experienced hands.
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What this paper adds
Patients with a ruptured AAA are often excluded for EVAR based on aortic 
morphology. This paper evaluates technical and clinical outcome of emergency 
EVAR in patients with hostile infrarenal aortic neck anatomy and reports excellent 
results, suggesting that emergency EVAR in ruptured AAA with hostile aortic neck 
anatomy is technically feasible and safe in experienced hands.
Introduction
A ruptured abdominal aortic aneurysm (RAAA) is fatal without emergency surgical 
intervention. The first report of a successful endovascular treatment of RAAA was 
published in 1994.1 With doctors becoming more experienced in endovascular 
techniques and due to the improved availability of off-the-shelf endografts, an 
increasing number of RAAA patients undergo endovascular treatment. Endovascular 
aneurysm repair (EVAR) might improve short-term survival rates of RAAA patients 
compared to traditional open surgical repair (OR).2 The implementation of an 
EVAR-first strategy for RAAAs in experienced centres shows an improved clinical 
outcome.3 However, according to the best available data, the IMPROVE trial, the 
AJAX trial and a recent meta-analysis, there is no significant difference in short-
term survival rates between EVAR and OR.4-6
The choice between OR and EVAR is based on operator preference, patient 
characteristics and anatomic suitability. Anatomic suitability is defined in the 
instructions for use (IFU) of each endograft. With the evolution of endografts, the 
anatomic suitability for EVAR increased from 20% to approximately 46-64% with 
current devices.4, 5, 7 Unfavourable anatomy of the aneurysm and adverse anatomic 
characteristics of the aortic neck could be predictors of poorer short-term 
outcomes.8 However, in experienced endovascular centres, an increasing number 
of patients with an abdominal aortic aneurysm (AAA) are treated outside the IFU. 
In our experience, this certainly includes RAAAs.
This study aimed to compare the 1-year results of EVAR for RAAA patients with 
favourable aortic neck anatomy (FNA) and hostile aortic neck anatomy (HNA).
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Methods
Patient selection
Patients with a proven RAAA were retrospectively identified based on the Dutch 
administrative code for RAAA (406) in the hospital records of a large, tertiary 
referral centre for cardiovascular disease in the Netherlands. Patients were 
included for this analysis if the RAAA had been treated by means of EVAR between 
February 2009 and January 2014. A RAAA was defined as bleeding outside the 
adventitia of a dilated aortic wall. The diagnosis of a ruptured AAA was based 
on clinical findings, an ultrasound (US) in the emergency department, followed 
by a contrast-enhanced computed tomography angiography (CTA) to confirm the 
diagnosis and allow for precise treatment planning. Patients were excluded if 
there was no evidence of a rupture. Patients who underwent previous EVAR or OR 
were also excluded.
Patients’ clinical status, medical history, treatment and follow-up data were 
collected through hospital, emergency department and operation records. 
Patient management
All patients were treated by (or under the supervision of) an experienced 
endovascular surgeon. The type of treatment (OR or EVAR) was left to the discretion 
of the surgeon, though under an EVAR-first strategy. All patients scheduled for 
endovascular treatment underwent preoperative CTA to determine baseline 
aortic and aneurysmal dimensions. Both bifurcated and aorto-uni-iliac (AUI) 
devices were used, including Endurant (Medtronic Vascular, Santa Rosa, CA, USA) 
and Excluder (W.L. Gore and Associates, Flagstaff, Ariz, USA). All endografts were 
implanted through the common femoral artery via a transverse surgical cutdown.
If the prognosis due to comorbidity was exceedingly poor or if treatment options 
were limited, patients were palliated. Standard follow-up of treated RAAA patients 
was performed at one month with a CTA scan, and yearly thereafter with CTA or 
duplex ultrasound.
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Anatomic evaluation
Two trained researchers independently and blinded for treatment outcome, 
reviewed all available preoperative CTAs. Measurements were made using 
dedicated three-dimensional (3D) sizing software (3mensio; 3mensio Vascular; 
Bilthoven, The Netherlands). Central lumen line (CLL) was generated manually. 
Measurements were taken perpendicular to the CLL, and suprarenal and infrarenal 
angulations were determined according to the method described by Van Keulen 
et al..9 In case of a discrepancy of more than two millimetres neck length or 
five degrees angulation, consensus was obtained by consultation of one of the 
endovascular surgeons. A common iliac artery (CIA) with a diameter ≥17 mm in 
males or ≥15 mm in females was considered aneurysmal.10 
Definitions and outcomes
For this study we divided our cohort of patients into two groups based on infrarenal 
aortic neck anatomy. FNA was defined as RAAAs with a proximal neck of ≥15 mm 
combined with a suprarenal angulation (α) ≤60° and an infrarenal angulation (β) 
≤75° or defined as a proximal neck of ≥10 mm combined with α ≤45° and β ≤60°. 
HNA was defined as RAAAs with a proximal neck of <10 mm, or a proximal neck of 
10 - 15 mm with α >45° and/or β >60°, or a proximal neck of >15 mm combined with 
α >60° and/or β >75°. The limits correspond with the instructions for use (IFU) for 
the Endurant stent graft.
Technical success was defined as successful delivery and deployment of the 
endograft, without unintentional coverage of renal or visceral arteries, followed 
by successful removal of the delivery system, and the absence of either a type I 
or III endoleak. Completion angiography was performed to document any possible 
endoleaks and other endograft-related complications. The duration of procedure 
was defined as the time between arterial cut down and closure. Thirty-day and 
one-year outcomes included endograft-related complications, mortality rates, 
and need for secondary interventions. Significant migration was defined as a 
displacement of the endograft of ≥10 mm. There was no loss to follow-up at one-
year.
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Statistical analysis
Statistical analyses were performed using SPSS version 21 for MAC (IBM 
Corporation, Armonk, NY, USA). Categorical variables are presented as frequencies 
with percentages. The χ2 or Fisher’s exact test were used for categorical variables 
depending on sample size. Continuous variables are presented as mean ± 
standard deviation (SD) or as median and interquartile range (IQR) in case of 
skewed data. Mean differences were assessed using independent group t-tests 
and median differences were assessed using Mann-Whitney U tests. A p-value <.05 
was considered statistically significant. A per protocol analysis was performed for 
the technical endograft-related observations. All other variables were evaluated 
on an intention-to-treat basis. Missing values were excluded for analysis. Follow-
up data were analysed by Kaplan-Meier life-table analysis and the log-rank test.
Results
Patients
A total of 69 patients presented with a RAAA at our emergency department 
between February 2009 and January 2014. Six patients were rejected for surgery 
based on extensive co-morbidities and 4 did not regain cardiac output after 
cardiopulmonary resuscitation. Of the 59 patients that underwent an intervention, 
12 patients (20%) underwent OR. Primary reason for OR was the presence of a 
juxtarenal aneurysm. The remaining 47 patients (80%) underwent EVAR; 8 of these 
patients were excluded because they had a secondary rupture after previous AAA 
repair (5 OR and 3 EVAR). The remaining 39 patients were included in the present 
study. The FNA group consisted of 22 patients (56%), and the remaining 17 patients 
(44%) were assigned to the HNA group. 
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Preoperative clinical and anatomic features
Demographic data, haemodynamic status, serum creatinine, haemoglobin, and 
baseline risk factors of the study groups are outlined in Table 1. There were no 
signifi cant differences in age, gender, haemodynamic stability and risk factors. 
Mean preoperative AAA measurements are listed in Table 2. The HNA group tended 
to have a larger maximum AAA diameter (HNA 86 ± 15 mm vs. FNA 70 ± 18 mm, p = 
.004). The shortest proximal neck was 4 mm and the largest α and β were 85° and 
90°, respectively. In the HNA group, seven (41%) patients had a proximal aortic 
neck length <10 mm, seven (41%) patients had a suprarenal angulation >60°, and 
11 (65%) patients had an infrarenal angulation >75°.
Table 1. Patient demographics and risk factors by neck anatomy.
a Values are reported as mean ± standard deviation, median and interquartile range 
(IQR) or as frequencies (%) (n/N).
b T-test
c Fisher’s Exact test
d Kruskal-Wallis test
e Pearson Chi-Square
Denominator differs when there are missing values.
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Intraoperative results
Operation time was signifi cantly longer for HNA (HNA 122 (IQR 88-179) mins vs. FNA 
87 (IQR 65-104) mins p = .021). There was trend of implanting more AUI devices 
in HNA patients however not signifi cantly different (Table 3). No endograft was 
implanted in one HNA patient because of iliac access diffi culties. Due to severe 
co-morbidities, this patient was not converted to open surgery and died within 
24 hours. Intraoperative type IA endoleaks were more frequent in the HNA group. 
However, all endoleaks were addressed and resolved during the initial procedure. 
All intraoperative endoleaks required the use of a balloon-expandable stent and 
in one patient an extension cuff was added. Unintentional overstenting of both 
renal arteries occurred in one HNA patient. A hepatorenal bypass was performed 
to preserve blood fl ow to one kidney. Technical success was 100% (22/22) for FNA 
and 88% (15/17) for HNA (p = .184). Two FNA patients (9%) and two HNA patients 
(12%) died within 24 hours after surgery.
Table 2. Baseline aneurysm characteristics by neck anatomy.
a Values are reported as mean ± standard deviation or as frequencies (%) (n/N). 
b Abdominal aortic aneurysm
c T-test
d Pearson Chi-Square
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Thirty-day outcome
Within 30 days after implant, 3 FNA patients (13%) died, versus 2 HNA patients 
(12%, p = 1.000), including the direct postoperative deaths. One-month imaging 
was performed in 33 implanted patients (85%), one patient was diagnosed with 
metastasised cancer therefore no follow-up was planned. Table 4 presents the 
30-day clinical and technical outcomes. One FNA patient developed a type IA 
endoleak on postoperative day one, which required open surgical correction. 
Unfortunately, the patient died during this procedure. One HNA patient was 
converted to open repair due to an AAA re-rupture based on a type IA endoleak 
on postoperative day three. One type IB endoleak was reported in an HNA patient, 
requiring an extension cuff just to the level of the hypogastric artery. An endograft 
limb occlusion was observed in an FNA patient, which was corrected by converting 
the bifurcated graft to an AUI graft in combination with a femoro-femoral bypass.
Table 3. Initial procedural data and evaluation by neck anatomy.
a Values are reported as median and interquartile range (IQR) or as frequencies (%) 
(n/N). 
b Aorto-uni-iliac
c Kruskal-Wallis test
d Pearson Chi-square
e Fisher’s Exact test
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A total of four HNA patients (24%) versus zero FNA patients developed an abdominal 
compartment syndrome, which required decompression laparotomy (p = .029). 
One-year outcome
One-year imaging was available for 28 (72%) patients. No new type I endoleaks 
were reported in either group. One FNA patient developed a type III endoleak, 
which was endovascularly corrected with an interposition graft. Freedom from 
device-related secondary interventions at 1 year was comparable between groups 
(FNA 85% vs. HNA 87%, p = .962, Figure 1). In addition, there were no signifi cant 
differences in estimated freedom from all-cause mortality (FNA 77% vs. HNA 
65%, p = .413, Figure 2). Within 1-year four HNA patients died (urosepsis, sepsis 
of unknown origin, cardiac, incarcerated femoral hernia). In the FNA group two 
patients died (metastasised cancer, pulmonary insuffi ciency). In all patients there 
were no stent graft related complications. 
Table 4. Patient outcome within 30-days by neck anatomy.
a Values are reported as frequencies (%) (n/N). 
b Per protocol analysis. Only patients with 30-day imaging were included in the 
analysis.
c Intention-to-treat analysis. All patients were included in the analysis.
d Abdominal compartment syndrome
e Fisher’s Exact test
101Endovascular treatment of ruptured abdominal aortic aneurysms with hostile aortic neck anatomy
Table 5. Patient outcome at 1-year by neck anatomy
Figure 1. Kaplan-Meier curves representing the 1-year freedom 
from device-related secondary interventions. Log-rank, p = .962.
a Values are reported as frequencies (%) (n/N). 
b Per protocol analysis. Only patients with 1-year imaging were included in the 
analysis.
c Fisher’s Exact test
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Discussion
To the best of our knowledge, this is the fi rst report that evaluates the outcomes 
of EVAR in RAAAs with hostile aortic neck anatomy. We report encouraging results 
with no differences in clinical and technical outcomes between FNA and HNA 
patients.
Mortality is of the utmost importance in the discussion whether patients with 
hostile anatomical features should be treated with EVAR. In our study, following an 
EVAR-fi rst strategy, the overall 30-day or in-hospital mortality was 13%. This is in 
line with reports showing an improvement in 30-day mortality in various centres 
that changed from an OR-fi rst to an EVAR-fi rst approach.11 When taking aneurysm 
morphology into account it has been shown that especially short infrarenal neck 
length infl uences mortality, as it does in OR.12 in OR this is most likely caused by 
the need for high cross-clamping, impairing circulation of the visceral arteries. 
In our study the mortality rates were not infl uenced by the suitability for EVAR 
(FNA 14% vs. HNA 12% p = 1.000). This supports our view that patients should 
not be denied endovascular surgery based on hostile anatomical features alone. 
Especially when considering that data on emergency EVAR in HNA are limited and 
Figure 2. Kaplan-Meier curves representing the 1-year freedom 
from all-cause mortality. Log-rank, p = .413.
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OR in this population shows no survival benefit.12
In our study, 44% of patients undergoing EVAR had HNA. This is in contrast with 
reports estimating that 17% to 30% of elective patients are treated outside IFU.13, 
14 Anatomic unsuitability for EVAR remains one of the main reasons to treat AAAs 
via open surgery, and there have been reports stating that up to 80% of RAAAs are 
regarded as not suitable for EVAR.7 However, unsuitability is based on preclinically 
obtained test data and defined by the manufacturer. With increasing experience, 
off-label use of several stent grafts has become widely accepted in elective 
surgery. 
The discrepancy between our results and previous reports on suitability can partly 
be explained by the fact that juxtarenal AAAs underwent OR and were not included 
in this analysis. However, this does not account for the difference between elective 
and emergency EVAR. One reason for the high number of patients treated with 
HNA can be the diameter of the AAA. In this study, the mean AAA diameter was 
significantly larger for HNA patients. Besides increasing the risk of a rupture, a 
large AAA diameter may also negatively influence infrarenal neck length or shape, 
or both, which can result in a higher percentage of RAAAs regarded as unsuitable 
for EVAR.7 Although our study shows no difference at 1-year between HNA and FNA, 
the larger AAA diameter could attribute to a higher reintervention rate at long-
term follow-up as has been previously described.15
Our results did show a significantly higher rate of adjunctive procedures for 
intraoperative type IA endoleaks in HNA patients. Comparable results can be 
found in studies reporting the outcome of EVAR in elective AAA patients with 
hostile infrarenal necks. A recent meta-analysis of these studies also concluded 
that patients with hostile neck anatomy required significantly more adjunctive 
procedures to resolve intraoperative type IA endoleaks (FNA 9% vs. HNA 22%, p< 
.001).16 Remarkably, however, our study reported a comparable rate of adjunctive 
procedures of 24% in HNA patients, even though there was notably less time for 
procedure planning compared to elective surgery. This indicates that emergency 
planning by an experienced vascular surgeon was adequate, and did not lead to 
an increased need for adjunctive procedures. 
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Although EVAR requires a lifelong follow-up and has an increased secondary 
intervention rate compared to OR, we found no differences in the need for 
secondary interventions between HNA and FNA within one-year. This finding 
is in line with previous reports on AAAs with challenging aortic necks treated 
with comparable devices in an elective setting.17-19 This implies that the need for 
secondary interventions within one year of follow-up was not influenced by the 
emergency setting and the higher number of adjunctive procedures in our study. 
A marked advantage of EVAR is that its physiological impact is notably reduced 
compared to OR, due to the possibility of local anaesthesia and the avoidance of 
aortic cross clamping. A recent study by Gupta et al. supports this theory with an 
improved mortality in unstable patients who received EVAR.20 On the other hand, 
the AJAX-trial and IMPROVE-trial did not show any significant differences in 30-
day mortality between EVAR and OR.4, 5 However, it should be noted that these two 
randomised trials reported only on a selected group of patients with RAAA and 
are not necessarily generalizable to the general population. Moreover, the nature 
of these trials did not permit surgeons to perform the procedure they personally 
prefer.
While our study suggests that a hostile infrarenal neck is not necessarily a reason 
for OR, there are limitations to the use of a ‘regular’ endograft, depending on the 
extent of neck hostility. Several techniques have been developed to increase EVAR 
suitability, one of which is the chimney technique introduced by Greenberg et al..21 
This is a cheap and readily available procedure and therefore ideal for RAAAs. 
However, evidence is scarce and consists of small studies, case reports without 
long-term follow-up.22
Even without advanced techniques, we reported a low percentage (14%) of RAAA 
patients rejected for intervention. This finding may inform the debate on rejection 
for repair, which is considered to be subject to many influencing factors. In current 
literature, rejection rates vary greatly between centres and countries, ranging from 
20% to up to 42%.23 These differences arise because a large variation of criteria is 
used to decide whether or not to operate on a patient. Some of the patients are 
rejected for any form of surgery because anatomy does not allow EVAR and co-
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morbidity precludes OR. 
In our hospital, treatment decisions are based on a multitude of anatomical 
and patient characteristics. Therefore, our patient sample ranges from 
small haemodynamically stable retroperitoneal haemorrhaging to large free 
intraperitoneal ruptures. While open surgery is probably lethal in the latter 
patients, they may potentially survive EVAR in combination with optimized in-
hospital logistics (availability of preoperative CT, an experienced endovascular 
team and immediate availability of a variety of endografts) and the use of 
permissive hypotension.3 
In clinical practice, a CT scan is essential, even in an emergency setting, to 
determine the best surgical care and to make a substantiated decision to perform 
open or endovascular surgery. A previous study suggests that, in a majority of 
RAAA patients, there is enough time to obtain CT imaging, assess AAA morphology 
and EVAR suitability, and transfer the patient to the operating theatre.24 
Study limitations
This study is limited by the small sample size and the single-centre design. Due to 
the low rate of complications, modern stent grafts require a larger patient sample 
to detect significant differences. We described the results of emergency EVAR in 
a hospital with three vascular surgeons performing over 100 EVARs annually. Our 
results may not be generalizable to centres with less experience in EVAR. Further 
prospective studies, with a larger group of patients, and longer follow-up are 
necessary to evaluate the safety and durability of EVAR in patients with RAAAs 
and hostile infrarenal aortic neck anatomy. 
Conclusion
EVAR in RAAAs with hostile infrarenal aortic necks appears technically feasible and 
safe in experienced hands. Endograft-related complication rates and secondary 
intervention rates were not significantly higher in RAAA patients with HNA at 
1-year.
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Abstract
Objective: This study aimed to compare perioperative and postoperative outcomes 
after endovascular repair of abdominal aortic aneurysms (AAA) in patients with 
various neck morphologies. 
Methods: Data from the ENGAGE Registry were used for the analyses. Patients were 
categorized into three different groups according to proximal aortic neck anatomy: 
regular (REG), intermediate (INT), and challenging (CHA). REG was defined as AAAs 
with a proximal neck ≥ 15 mm combined with a suprarenal angulation (α) ≤ 45° and 
an infrarenal neck angulation (ß) ≤ 60°. INT was defined as AAAs with a proximal 
neck of 10-15 mm combined with α ≤ 45° and ß ≤ 60° or with a proximal neck of > 
15 mm combined with α ≤ 60° and ß = 60°-75° or α = 45°-60° and ß ≤ 75°. CHA was 
defined as infrarenal necks that exceed at least one of the three defining factors.
Results: Overall, 925 patients (75.9%) had REG anatomy, 189 patients (15.5%) had 
INT anatomy, and 104 patients (8.5%) had CHA anatomy. Patient demographics 
and risk factors were similar. There was a significant difference in AAA diameter 
between the REG and CHA group (59.4 mm vs. 65.2 mm, P < .001). Technical success 
was similar among groups (REG 99.1% vs. INT 99.5% vs. CHA 97.1%). There were no 
differences in mortality or the need for secondary procedures within 30 days or 
at 1 year. A significantly higher rate of type-I endoleaks within 30 days was seen 
in CHA compared with REG and INT (adjusted OR  0.15, 95% CI  0.05 - 0.46 and 
adjusted OR  0.08, 95% CI  0.01 - 0.70, respectively), but there was no difference at 
the 1-year follow-up. 
Conclusions: This real world, global experience shows promising results and 
indicates that endovascular AAA repair with the Endurant Stent Graft is safe and 
effective in patients with challenging aortic neck anatomy. However, long-term 
follow-up of patients is required to confirm results. 
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Introduction
There have been substantial changes in the treatment of abdominal aortic 
aneurysms (AAAs) since the introduction of endovascular aortic aneurysm repair 
(EVAR) in 1991.1 The success of an EVAR procedure, in terms of exclusion of the 
aneurysm and absence of perioperative and postoperative complications, is 
closely dependent on the AAA’s morphology and dimensions.2 For this reason, 
each commercially available endograft comes with its own instructions for use 
(IFU) with clear recommendations on AAA morphology and aortic dimensions. 
Short infrarenal aortic necks and/or severe infrarenal aortic neck angulation are 
likely to cause more intraoperative and postoperative complications such as graft 
migration and type I endoleaks.3-5 
A substantial proportion of AAA patients is not eligible for EVAR, due to presence 
of anatomy outside the endograft inclusion criteria.6 Unfortunately, these patients 
are often also considered to be less attractive for open surgery.7 However, as 
practitioners become more experienced with endovascular therapy and with 
improved stent graft technology, increasing numbers of patients with challenging 
AAA morphology are treated with EVAR. 
The main objective of this study was to compare the outcomes of EVAR with a 
latest-generation stent graft system in different infrarenal aortic neck anatomies 
within the context of contemporary, real-world practice. Retrospective analysis 
was performed on data from the Endurant Stent Graft Natural Selections Global 
Postmarket Registry (ENGAGE).
Methods
Study design
ENGAGE is a multi-center, non-randomized, prospective observational study of 
patients treated with the Endurant Stent Graft System (Medtronic Vascular, Santa 
Rosa, CA, USA). This endograft is specifically designed to broaden the EVAR eligibility 
range. To reflect real-world clinical practice, the eligibility criteria for ENGAGE were 
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minimal and enrollment of patients outside Endurant’s IFU was accepted. Patients 
needed to be at least 18 years old and have an indications for elective AAA repair. 
The only exclusion criteria were the probability of non-adherence to follow-
up requirements and the concurrent participation in another trial that might 
confound results. Centers were selected based on a minimal annual case volume 
of 20 AAA stent graft procedures in combination with a history of minimal three 
successful Endurant stent graft procedures. To avoid selection bias, participating 
sites were requested to enroll patients consecutively. Ruptured AAAs were not 
considered for enrollment into ENGAGE. The trial was conducted according to the 
Declaration of Helsinki and the International Conference on Harmonization (ICH) 
Good Clinical Practice (GCP) guidelines, and approved by local medical ethics 
committees. The study is registered on clinicaltrials.gov (NCT00870051). Technical 
specifications of the Endurant Stent Graft System and further methodological 
details of the ENGAGE Registry have been published previously.8, 9
Definitions and study endpoints
For this retrospective analysis, the study population was partitioned based on 
the IFU criteria of the Endurant. We created three groups divided according to 
anatomical complexity of the infrarenal neck: regular (REG), intermediate (INT) 
and challenging (CHA) (Table 1). Suprarenal angulation (α) was defined as the angle 
between the flow axis of the suprarenal aorta and the infrarenal neck. Infrarenal 
angulation (ß) was defined as the angle between the flow axis of the infrarenal 
neck and the body of the aneurysm. REG was defined to include AAAs with a 
proximal neck of > 15 mm combined with α ≤ 45° and ß ≤ 60°. INT was defined to 
include AAAs with a proximal neck of 10-15 mm combined with α ≤ 45° and ß ≤ 60° 
or with a proximal neck of > 15 mm combined with α ≤ 60° and ß = 60°-75° or α = 
45°-60° and ß ≤ 75°. CHA was defined to include infrarenal necks that exceed at 
least one of the three defining factors (i.e., neck length < 10 mm, or a neck length 
of 10-15 mm with α > 45° and/or ß > 60°, or a neck length > 15 mm combined with α 
> 60° and/or ß > 75°). All patients underwent computed tomography angiography 
(CTA) preoperatively to determine baseline aortic and aneurysmal dimensions. 
CTA measurements were performed by the participating centers and not reviewed 
by a central CORE-lab. Pre-existing medical comorbidity information was collected 
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immediately after patient enrollment. It was recommended to have annual follow-
up imaging after the index procedure. The fi rst choice of imaging modality was a 
CTA. 
Table 1. Classifi cation of patients based on anatomy of the proximal nonaneurysmal 
infrarenal neck. 
Regular anatomy: N = 925, Intermediate anatomy: N = 189, Challenging anatomy: N = 
104
Technical success was defi ned as successful delivery and deployment of the 
Endurant endograft, without unintentional coverage of renal arteries, internal 
iliac arteries or visceral branches, with absence of either a type I or III endoleak, 
followed by successful removal of the delivery system.10 A completion angiogram 
was performed to document the status of endograft implantation. The necessity of 
proximal extension cuff placement to correct peroperative type 1A endoleaks was 
documented. Duration of implant procedure was defi ned as the time between cut-
down or puncture and removal of the last guide wire. Fluoroscopic time, volume 
of contrast, post-operative stay and possible intensive care unit (ICU) admission 
were documented. Thirty-day and 1-year outcomes included endograft-related 
complications, mortality rates, and need for secondary interventions. Technical 
complications included; occlusion (100% stent graft obstruction); stenosis (partial 
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stent graft obstruction); kinking (stent graft obstruction in the horizontal plane); 
and migration (stent graft movement >10mm). All patients completed 1-year 
follow-up.
Data collection and statistical analysis
The clinical investigators recorded data on a web-based electronic case report 
form to ensure reliable data collection, data management, secure authentication, 
and traceability. All entered data were reviewed and more than 40% of patients’ 
source documentation was monitored randomly. Each center’s institutional review 
committee approved the Registry and informed consent was obtained from all 
patients.
Categorical variables are presented as frequencies (percentages). Continuous 
variables are presented as mean ± standard deviation or as median and interquartile 
range in the case of skewed data. Differences in baseline characteristics among 
the three study groups were analysed using the χ2 test for discrete variables 
and the ANOVA or the Kruskal-Wallis test for continuous variables. Differences 
among study groups were tested using the Bonferroni multiple-comparison 
test. Multivariate logistic and linear regression analyses were used to adjust for 
possible confounding factors. Multicollinearity was checked using the variance 
inflation factor and the tolerance. A P-value < .05 was considered statistically 
significant. All statistical analyses were performed using SPSS® version 21 for MAC 
(IBM Corporation, Armonk, NY, USA).
Results
Between March 2009 and April 2011, 1263 AAA patients treated with an Endurant 
were enrolled from 79 sites in 30 countries worldwide. We excluded 45 patients 
with insufficient baseline data on aortic morphology. Data for the remaining 
1218 patients comprise the basis of this report. REG anatomy was present in 925 
patients (75.9%), INT anatomy in 189 patients (15.5%), and CHA anatomy in 104 
patients (8.5%).
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Baseline characteristics
Demographic data and baseline risk factors of the study groups are outlined in 
Table 2. There was a signifi cant difference in the distribution of sexes, with the 
most females in the CHA group (P = .001). There were no differences in age or 
American Society of Anaesthesiologists (ASA) classifi cation among the groups. 
The prevalence of cancer and gastro-intestinal complications were signifi cantly 
different among the groups (P = .009 and P = .036, respectively). 
Table 2. Demographics and risk factors in patients grouped by neck anatomy.
REG, Regular anatomy; INT, Intermediate anatomy; CHA, Challenging anatomy; ASA, 
American Society of Anaesthesiologists; AAA, abdominal aortic aneurysm.
a Values are reported as mean ± standard deviation or frequencies (%) (n/N). 
Denominator differs when there are missing values.
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Baseline aneurysm characteristics are shown in Table 3. The CHA group had larger 
maximum AAA diameters on average compared with the REG group (P < .001). There 
was no signifi cant difference in proximal non-aneurysmal neck length between 
INT and CHA (P = .162). Suprarenal and infrarenal neck angles were signifi cantly 
different among all groups (all P < .001). Proximal neck diameter and bilateral iliac 
fi xation site diameters were comparable among groups.
Table 3. Baseline aneurysm characteristics by neck anatomy.
REG, Regular anatomy; INT, Intermediate anatomy; CHA, Challenging anatomy; AAA, 
Abdominal aortic aneurysm.
a Values are reported as mean ± standard deviation or as median and interquartile 
range in case of skewed data.
Intra-operative outcome
Initial procedural data and evaluations are detailed in Table 4. Operation time 
was signifi cantly longer in the CHA group compared with the REG and INT groups 
(adjusted P < .001 and adjusted P = .001, respectively). Signifi cantly more contrast 
was used in CHA compared with REG (127.0 cc vs. 152.7 cc, adjusted P = .001). 
Fluoroscopic time was signifi cantly longer in INT and CHA compared with REG 
(adjusted P = .033 and adjusted P < .001, respectively). No differences in post-
operative stay or ICU admission rate were noted among groups.
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Table 4. Initial procedural data and evaluations.
REG, Regular anatomy; INT, Intermediate anatomy; CHA, Challenging anatomy; OR, 
Odds ratio; ICU, Intensive care unit.
a Values are reported as mean ± standard deviation or frequencies (%) (n/N). 
Denominator differs when there are missing values.
b Adjusted for Gender, Cancer, Gastro-intestinal complications, Maximum AAA 
diameter.
c Signifi cantly different
Four patients required immediate conversion to open surgery, of whom three were 
in the REG group and one in the CHA group. Among the REG patients, two required 
open surgery because of diffi culties passing the iliac arteries and one because 
of unintentional coverage of both renal arteries. The CHA patient was converted 
to open surgery because the surgeon was unable to remove the delivery device 
when a suprarenal strut became entrapped in the delivery system. Incidences of 
type I and type III endoleaks were distributed equally among the groups. However, 
signifi cantly more proximal extension cuffs placements were necessary to correct 
peroperative type 1A endoleaks in the CHA group compared to the REG group. 
There were no signifi cant differences in technical success among the groups. No 
patients died during the procedure. 
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Thirty-day outcome
Thirty-day outcomes are summarized in Table 5. Twelve REG patients (1.3%), one 
INT patient (0.5%), and three CHA patients (2.9%) died within 30 days of implant. 
Only one ruptured AAA was reported (in a REG patient), which did not result in a 
signifi cant difference among groups. Two REG patients and one CHA patient were 
converted to open surgery (adjusted OR 0.33, 95% CI 0.02 – 4.46). We observed no 
signifi cant differences in secondary interventions.
Table 5. Patient outcomes within 30-days.
REG, Regular anatomy; INT, Intermediate anatomy; CHA, Challenging anatomy; OR, 
Odds ratio.
a Values are reported as mean ± standard deviation or frequencies (%) (n/N). 
Denominator differs when there are missing values.
b Adjusted for Gender, Cancer, Gastro-intestinal complications, Maximum AAA 
diameter.
c Signifi cantly different
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Type I endoleaks occurred in seven REG patients (0.8%), one INT patient (0.6%), 
and seven CHA patients (7.4%). The incidence of type I endoleaks was significantly 
higher in the CHA group (REG vs. CHA: adjusted OR 0.15, 95% CI 0.05-0.46 and 
INT vs. CHA: adjusted OR 0.08, 95% CI 0.01-0.70). No differences were noted in 
rates of type III endoleak, stent graft occlusion, stent graft stenosis, or stent graft 
migration. Stent graft kinking was significantly more prevalent in CHA compared 
with REG (adjusted OR 0.29, 95% CI 0.09-0.95). Notably, only two patients (one INT 
and one CHA) suffered stent graft kinking in the proximal aortic neck.
One-year outcome
There were no significant differences regarding all-cause and AAA-related mortality 
among groups within 1 year of endograft implantation (Table 6). Furthermore, 
there was no significant difference in secondary procedure rates. Conversion 
to open surgery was comparable among groups and was necessary in four REG 
patients (0.4%), two INT patients (1.1%), and one CHA patient (1.0%).
At one year, endoleak type I and III rates were not significantly different among 
groups. Stent graft stenosis was significantly more prevalent in CHA versus REG 
(adjusted OR = 0.22, 95% CI = 0.05-0.92). No statistical differences were found 
among groups with respect to stent graft occlusion, kinking, or migration.
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Table 6. Patient outcomes at 1-year.
REG, Regular anatomy; INT, Intermediate anatomy; CHA, Challenging anatomy; OR, 
Odds ratio.
a Values are reported as mean ± standard deviation or frequencies (%) (n/N). 
Denominator differs when there are missing values.
b Corrected for Gender, Cancer, Gastro-intestinal complications, Maximum AAA 
diameter.
c Signifi cantly different
Discussion
We created three anatomic groups to gain better insight into the infl uence of 
aortic neck length and angulation on EVAR outcomes. The REG criteria are within 
the IFU criteria for the Talent Abdominal Stent Graft (Medtronic Vascular, Santa 
Rosa, CA, USA), whereas the INT criteria include the Talent indication as well as 
the broader indications specifi ed in the Endurant IFU. The CHA patients had aortic 
neck characteristics outside both the Talent and Endurant IFUs. 
Advances in technology, imaging, and operator experience have led to an 
extension of the use of EVAR beyond initial manufacturers’ guidelines. Nowadays, 
an increasing number of patients with more challenging anatomies of the proximal 
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infrarenal neck are treated with conventional EVAR. The performance of the 
Endurant Stent Graft in challenging anatomy was evaluated in previous reports, 
and showed no differences in operative success rate and early outcome.11-14 
However, these studies consisted of small, retrospective patient groups with 
possible selection bias. The results of this study are in line with previous findings, 
showing comparable perioperative results among anatomic groups.
We report more type I endoleaks within 30 days for CHA patients. However, these 
were not seen at final angiogram or at 1-year follow-up. Type I endoleaks result in 
direct blood flow in the aneurysm sac, causing further dilatation and, eventually, 
rupture of the aneurysm sac. Despite this possible danger, a conservative approach 
to small intraoperative type I endoleaks may be justified in selected patients.15 In 
this study, 13 type I endoleaks were seen at final angiogram, of which 10 type I 
endoleaks (76.9%) resolved spontaneously within 30 days of the procedure. Two 
type I endoleaks were successfully corrected after secondary intervention. One 
patient died within 30 days due to cardiac arrest.
According the European guidelines, all delayed type I endoleaks should be 
treated.16 At 1-month follow-up, 15 type I endoleaks were seen, of which 11 were 
corrected with a secondary intervention and 1 with open surgery. Three type I 
endoleaks remained uncorrected, of which 2 resolved spontaneously. One patient 
died, but this was unrelated to the uncorrected type I endoleak. At the 1-year 
follow-up, there were 4 new type I endoleaks, which were all corrected after 
secondary procedure.
Despite more stent graft-related complications in the CHA group at 30 days, the 
need for secondary procedures was equally distributed among groups. This is in 
line with previous reports on the use of the Endurant Stent Graft System outside 
the IFU.12-14
One could expect that technical success would be lower in challenging AAA 
anatomies. However, we found no significant difference in technical success rates 
among groups. We reported more contrast use and longer operation time for CHA 
patients. This may imply that the procedures were more complicated. In addition, 
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there was a more frequent use of proximal extension cuffs to correct peroperative 
type 1A endoleaks in the CHA group. A previous study on the ENGAGE database 
reported neck length as an independent risk factor for intra-operative neck 
related adverse events.17 In patients with challenging neck anatomy, preoperative 
planning with adequate sizing is of utmost importance. High image quality and 
optimal alignment of the C-arm in the cranial-caudal position is crucial to obtain 
maximum sealing in short necks.  
Patients in the CHA group had larger maximum AAA diameters compared with the 
REG group. Aneurysm size is a predictor of survival after EVAR.18 Torsello et al. also 
reported larger AAA diameters in patients with complex anatomies.14 Additionally, 
they found that patients with proximal aortic neck anatomy outside the IFU also 
presented with higher mean angulations of the iliac axis.13 Although we did not 
have information regarding iliac angulations for this analysis, this could explain 
the increased iliac stent graft kinking observed in the CHA group. Therefore, 
challenging anatomy of the infrarenal neck involves aneurysm size and probably 
the iliac axis.
Previous studies conclude that females have an increased risk for postoperative 
complications.19, 20 In addition, females have more often challenging aortoiliac 
anatomy than males.21 We also reported a higher percentage of female gender in 
the CHA group. In contrast however, the effect of gender on outcomes as studied 
previously in the ENGAGE Registry showed no differences in major adverse events 
and technical outcomes within one year.22 This can be explained by the use of the 
Endurant stent graft that may be better suited to overcome challenging aortoiliac 
anatomy in females compared to previous devices.  
A recent meta-analysis by Stather et al. reported increased 30-day mortality in 
patients with hostile infrarenal aortic necks.23 In contrast, we did not observe 
significant differences in survival among groups. The differences in outcomes 
could possibly be secondary to the application of other anatomic criteria for the 
classification of challenging infrarenal aortic necks in the studies included in the 
meta-analysis. The significant difference in 30-day mortality was mainly reported 
following an analysis of the EUROpean Collaborators on Stent-graft Techniques 
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for aortic Aneurysm Repair (EUROSTAR) data, which only evaluated the influence 
of infrarenal aortic neck length.24
Neck length and angulation have been reported as risk factors for device 
migration.5, 25 These findings were based on experience with first-generation 
endografts without active suprarenal fixation. The Endurant Stent Graft System 
includes anchoring pins to ensure active proximal fixation and prevent endograft 
migration. The present study reports no stent graft migration at 1-year follow-up 
in any of the anatomic groups. 
A limitation of the present study is the fact that we could not evaluate the effect 
of neck thrombus and calcification due to registry constraints. In addition, longer 
follow-up is necessary to evaluate the durability of the endograft in challenging 
anatomies. Also, our results could be influenced by low statistical power. An 
adequate number of patients with challenging anatomy needs to be added to 
this study to produce firm results and conclusions. The Endurant for Challenging 
Anatomy: Global Experience (EAGLE) Registry is currently enrolling patients 
with challenging anatomy to critically assess whether the current guidelines 
for anatomic eligibility for EVAR with the Endurant stent graft system are still 
applicable.26  
Conclusion
Patients with neck anatomy that is challenging in terms of severe angulation 
and short neck length can be treated successfully with the Endurant Stent Graft 
System. Technical success and mortality rates were comparable among groups. 
Despite an increased risk of type I endoleaks within 30 days, we did not observe an 
increase in secondary interventions. Extensive surveillance with annual imaging 
is recommended to detect and treat stent graft-related complications, especially 
in patients with challenging anatomy. Further prospective studies, with a larger 
group of patients and longer follow-up, are necessary to evaluate the safety and 
durability of the Endurant Stent Graft System in patients with challenging AAA 
anatomies.  
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Abstract
Aim: The aim of this study is to collect clinical information on the performance 
of the Endurant (II) Stent Graft System for endovascular repair in anatomically 
challenging infrarenal aneurysms, and to critically assess whether the current 
instructions for anatomic eligibility for endovascular treatment with this system 
are still applicable. 
Methods: Initiated by doctors, EAGLE is a prospective, non-interventional study, 
aiming to enrol 250 patients in 20 experienced centres across several countries 
worldwide. EAGLE focuses on patients with challenging angulation or neck length. 
To minimize the risk of selection bias and enhance data quality, EAGLE eligibility 
will be determined by an independent core-lab and efforts will be made to secure 
consecutive enrolment of challenging cases. The EAGLE database is designed to 
merge with the on-going ENGAGE database, which enables comparative analysis 
of cases and results. The primary endpoint is treatment success at 30 days, 12 
months and yearly up to 5 years post-implant.
Discussion: Separate studies on the performance of EVAR in challenging anatomy 
are necessary to demonstrate safety and effectiveness of the latest generation 
stent grafts, which is essential in making a balanced judgment about the optimal 
management of AAAs.
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Introduction
Over the past twenty years, endovascular aneurysm repair (EVAR) has been very 
successful in terms of the exclusion of aneurysms and the absence of perioperative 
and postoperative complications. Following to the instructions for use (IFU), the 
applicability of endografts to abdominal aortic aneurysms (AAAs) is restricted 
by AAA morphology and aortic dimensions. However, the management of AAAs 
has changed dramatically since Parodi et al.1 and Volodos et al.2 independently 
introduced EVAR in 1991.
According to several studies, the success of EVAR is closely dependent on an 
AAA’s morphology and dimensions.3,4 For this reason, the IFU for all commercially 
available endografts present clear recommendations on AAA morphology and 
aortic dimensions. If the device-specific IFU are strictly followed, a substantial 
proportion (40%) of patients must be rejected for having an anatomy that is 
unsuitable for EVAR, and more woman are rejected for EVAR than men.5 
Despite these stringent IFU, it is clear that patients with an anatomy outside 
the recommend limits are also being treated by means of EVAR. When reviewing 
anatomic measurement data at our centre, we found that numerous patients with 
shorter and more angulated infrarenal necks, outside the IFU, had been treated 
with an EVAR device. In the United States, a retrospective study of CT-scans of 
10,228 AAA-patients showed that 30% did not met the most liberal IFU criteria.4 
In the ENGAGE registry approximately 10% of the treated patients had angulated 
or short necks, outside the IFU criteria, despite the fact that Endurant’s IFU are 
liberal compared to other devices.4,7
Success rates and complication rates in these types of patients tend to be 
similar to those of patients who do meet the IFU criteria. These outcomes may 
be explained by the fact that the anatomic requirements defined in the IFU are 
based on research performed on first-generation endovascular stent grafts. Due 
to increased experience and improved devices, these criteria may therefore have 
become out-dated and may not be applicable to new-generation stet grafts, 
including the Endurant (II) System.
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Based on the encouraging initial results from the ENGAGE and our own centre’s 
experience, it is possible that with current devices even more challenging cases 
could be treated endovascularly. So far, however, no large prospective study 
on these outcomes has been performed. Evidence on this topic may create an 
opportunity for a broader group of AAA patients to be treated with this minimally 
invasive technique.
Therefore we designed the EAGLE (Endurant for Challenging Anatomy: Global 
Experience) Registry. The aim of this study is to prospectively collect global ‘real 
world’ data on the performance of the Endurant Stent Graft System for endovascular 
repair in anatomically challenging infrarenal AAAs and to critically assess whether 
the current recommendations for anatomic eligibility for endovascular treatment 
with this system are still applicable.
Methods
EAGLE is a multi-centre, post-market, non-interventional, non-randomized, single-
arm, prospective observational study, initiated by the Department of Vascular 
Surgery at Catharina Hospital Eindhoven, The Netherlands. The study has a single-
arm without controls, as it is descriptive in nature. With an anticipated percentage 
of success of 94%, sample size was calculated based on a hypothesis of non-
inferiority with a maximum of 10% difference. It will recruit approximately 250 
anatomically challenging subjects from 20 high-volume sites from 10 countries 
worldwide from September 2012 until December 2015. Study enrolment is open 
to consecutively enrolled subjects who in the opinion of the investigators are 
candidates for endovascular AAA repair with the Endurant Stent Graft System 
despite having challenging anatomic measurements. With the approval of the 
ENGAGE executive committee all patients within the ENGAGE dataset exceeding 
anatomic requirements (approximately 100 subjects) will also be included in the 
EAGLE comparative analysis.
EAGLE does not interfere with the physician’s decision whether or not to choose 
EVAR with an Endurant Stent Graft. Follow-up imaging studies are requested at 1 
month, 12 months, and yearly thereafter, as minimally required by the reporting 
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standards for endovascular aortic aneurysm repair.8 Beyond this, sites can 
schedule a subject’s follow-up visits as usual in their clinical practice, as this study 
does not interfere with or influence the follow-up regimen. For data completion 
it is, however, possible that a telephone contact with subjects will be requested.
Participating centres
Clinical sites with an annual case volume of more than 50 EVAR procedures and 
at least 25 successful prior Endurant implants are eligible to participate in the 
EAGLE Registry. Local ethical committees must approve participation in EAGLE. 
The initiating centre, Catharina Hospital, Eindhoven, the Netherlands, will also 
participate as one of the enrolling sites in the EAGLE Registry.
Device description
The Endurant Stent Graft is designed to treat infrarenal abdominal aortic or 
aorto-iliac aneurysms using an endovascular approach. When placed within the 
aneurysm, the Endurant Stent Graft provides a permanent, alternative conduit for 
blood flow within the subject’s vasculature by excluding the aneurysm sac from 
blood flow and pressurization.
Certain key features are present in the Endurant Stent Graft System, such as a 
design optimized to treat difficult anatomies with ≤75⁰ infrarenal neck angulation, 
a lower diameter profile to access and track small iliac vessels and a hydrophilic-
coated delivery system for improved handling. The Endurant Stent Graft also 
includes suprarenal anchoring pins for improved proximal fixation. 
The Endurant II Stent Graft System differs from its predecessor in three ways: 28 
mm-diameter bifurcated segment to fit inside an 18 French OD catheter (down 
from 20 French), addition of two new contralateral limb lengths (156 mm and 199 
mm), and improved radiopacity of the distal end of the bifurcated segment’s 
contralateral gate. 
The Endurant (II) Stent Graft System is indicated for the endovascular treatment 
of infrarenal abdominal aortic or aorto-iliac aneurysms in patients with the 
characteristics according the IFU (Table 1).
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Enrollment criteria
Participation in the EAGLE registry is intended for all subjects diagnosed with an 
infrarenal AAA whom their own physicians consider candidates for endovascular 
repair and who meet the inclusion criteria. EAGLE focuses on patients with 
challenging angulation or challenging neck length. To prevent selection bias, 
sites are requested to provide a minimal set of morphologic data of all patients 
scheduled for EVAR treatment with the Endurant Stent Graft from the moment a 
site participates in the EAGLE registry. To be included in the trial, patients need 
to be 18 years old and have an indication for elective EVAR with the Endurant (II) 
stent graft. AAA anatomy must be challenging as defi ned in the measurements 
described in table 2. 
Exclusion criteria are high probability of non-adherence to physician’s follow-up 
requirements or participation in a concurrent trial, because this may confound 
study results. Patients will also be excluded if adjuvant procedures at the proximal 
aortic neck are planned, such as chimney technique, branched device, fenestrated 
device or endostaplers. 
Table 1. Endurant® and Endurant® II instructions for use.
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Table 2. Inclusion and exclusion criteria EAGLE Registry
Subjects who meet all of the study eligibility criteria will be eligible for enrolment 
in the EAGLE study. An independent core-lab will crosscheck these considered 
patients’ appropriate imaging studies (Computed tomography angiography (CTA) 
with a minimal slice thickness of 3 mm) for EAGLE inclusion eligibility. The core-lab 
will be blinded for patient identity and for responsible physician. Subjects will be 
included if morphologic inclusion criteria are verifi ed by the core-lab. 
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Implantation and follow-up
The implant procedure shall be performed according to usual practice at the site 
and in line with the IFU. During the endovascular procedure it is at the investigator’s 
discretion to employ anesthesia, to administer antibiotics and systemic heparin, 
and to obtain and close access to the arterial site. All the devices should be 
deployed following all the steps in the IFU.
Use of an angiographic catheter with calibrated radiopaque marking is preferred. 
The investigator will verify dimensions and characterizations of each subject’s 
anatomy in relation to the Endurant Stent Graft System.
Each subject will continue to be followed according to the follow-up regimen that 
is standard clinical practice at each site. To be compliant to the protocol and 
current standard care in EVAR therapy, the subjects are requested to return to the 
sites for 1-year follow-up visits and annually thereafter until the 5-year visit at the 
end of the study. The 30-day visit will be considered the first visit after the initial 
implantation procedure and the timing of this visit may vary according to local 
follow-up regimes. 
Study endpoints
The primary endpoint of the EAGLE registry is treatment success at the time of 
the index procedure, at 30 days, 12 months and yearly up to 5 years post-implant. 
Treatment success is defined by technical success and clinical success. Technical 
success is defined as successful delivery and deployment of the Endurant Stent 
Graft in planned position without unintentional coverage of one or both internal 
iliac arteries or renal or visceral aortic branches and with successful removal of the 
delivery system. Clinical success is defined as freedom from aneurysm expansion 
of >5 mm, freedom from Type I and III endoleaks, freedom from aneurysm rupture, 
freedom from conversion to open surgery, and freedom from stent graft migration 
(> 10mm) and occlusion.
The secondary endpoints comprise technical observation, adverse events, major 
adverse events and quality of life. Technical observations include: presence of an 
endoleak, stent graft kinking, stent graft wire form fracture, suprarenal bare stent 
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fracture or detachment from fabric, stent graft occlusion or stent graft stenosis. 
Major adverse events include all-cause mortality, bowel ischemia, myocardial 
infarction, paraplegia, procedural blood loss ≥ 1000 cc, renal failure, respiratory 
failure and stroke. All deaths within 30 days after procedure are defined as 
aneurysm-related. Quality of life will be assessed before admission, after 
discharge, at 30 days, at 12 months and annually thereafter. Health outcome will 
be measured by the EuroQol 5-Dimensions (EQ-5D) questionnaire, which includes 
a visual analogue scale and a descriptive system.9 The EQ-5D questionnaire 
forms are designed for self-completion by subjects and will be provided in local 
language. 
Adverse event monitoring
Study-specific Adverse Events (AE) information will be collected throughout 
the study, documented in the subject’s medical record and reported to the 
coordinating centre on an Adverse Event e-CRF. For the purpose of the clinical 
report, we will classify each study-specific AE according to EN ISO 14155-1. Serious 
AEs will be reported to investigators, ECs and Regulatory Authorities according to 
national regulations and requirements.
Data collection and monitoring
Clinical data collection will only start after the subject has given voluntary, 
documented informed consent. Data collected will be recorded on appropriate 
web-based or paper format case report forms (CRFs). Instructions for proper 
completion of the CRFs may be printed at the sites to use as a working copy. The 
CRFs will be completed, reviewed, signed and dated by the clinical investigators. 
Data will be collected at baseline, during the implant procedure, throughout the 
hospital stay, and in the 5-year post-operative follow-up phase. 
All participating centres are monitored by a research team of the Department 
of Vascular Surgery, Catharina Hospital, Eindhoven to confirm adherence to 
the clinical investigational plan, to assess the accuracy and completeness of 
submitted clinical data, and to verify that records and documents are being 
properly maintained for the duration of the study. The Statistics & Data Analysis 
team at the Department of Vascular Surgery, Catharina Hospital, Eindhoven will 
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check the data entered on the CRFs for consistency and completeness on a regular 
basis, both manually as well as by means of statistical monitoring of the clinical 
database. Sites will be contacted for data inconsistencies in order to recover 
incomplete, inconsistent, or missing data. In case of multiple futile attempts at 
data completeness and non-response from clinical sites, sites will be visited by 
monitors of the Department of Vascular Surgery, Catharina Hospital, Eindhoven. 
In such cases, they will collect data from source documents in a final attempt 
to complete the applicable CRFs. To enhance data quality, additional site visits 
will be conducted to crosschecks CRFs with patient files in approximately 20% of 
enrolled subjects. 
Statistical analysis
Statistical analyses will take place after final subject’s 30-day follow-up, 1 year 
follow-up and thereafter annually. Statistical analyses will be performed using 
Predicting Analytics Software (SPAW/SPSS) for Mac (version 20 or more recent) or 
other validated statistical software. 
Discussion
Endovascular aneurysm repair (EVAR) is considered a safe and effective alternative 
to open repair for the treatment of selected cases of abdominal aortic aneurysm 
(AAA). The success of EVAR is, however, dependent upon patient-specific factors, 
including aortic dimensions and aneurysm morphology. Severely angulated or 
short infrarenal necks are associated with an increased risk of operative failure 
and late aneurysm rupture due to proximal Type-I endoleaks and graft migration. 
To limit these risks, IFU for commercially available stent grafts indicate use within 
a specific range of aortic anatomy. As a consequence, a substantial proportion of 
AAA patients are considered ineligible for EVAR as they fail to meet IFU criteria. 
In the past two decades, many technological advances have been introduced 
to improve feasibility and durability of EVAR. Also, surgeons have become more 
proficient in applying endovascular techniques. These developments have led 
to an increasing interest and confidence to extend treatment to challenging 
anatomies. Currently, >70% of elective AAA repairs are performed with EVAR, and 
139Rationale and design of the EAGLE Registry: EVAR with the Endurant in challenging anatomy
approximately 30% of these patients are considered outside IFU criteria.4 Multiple 
studies show comparable results in patients with conservative and challenging 
anatomy regarding mortality, proximal Type-1 endoleaks and reinterventions 
(Table 3). These studies indicate that EVAR with simple infrarenal stent graft 
placement can be used with caution in patients with unfavourable anatomy.10 
However the quality of the evidence in challenging cases is still scarce, due to a 
lack of long-term results and consecutive series. 
Therefore, the EAGLE (Endurant for Challenging Anatomy: Global Experience) 
Registry is designed to register the performance of the newest generation stent 
graft in challenging anatomy in a real-world setting, and to critically assess 
whether or not it is reasonable and safe to expand current guidelines of anatomic 
eligibility for endovascular treatment. To minimize the risks of selection bias and 
enhance data quality, EAGLE eligibility will be determined by an independent 
core-lab and efforts will be made to secure consecutive enrolment of challenging 
cases. 
The EAGLE Registry is unique and revolutionary in its design, aiming at a high 
number of challenging cases with a long-term follow-up. It will create a consecutive 
case series of the performance of EVAR in challenging anatomy with the latest 
generation stent graft. Future results from the EAGLE registry may reveal how far 
boundaries can be safely stretched, and broaden the applicability rate of EVAR.
Table 3. Overview of results in studies presenting Challenging and Friendly anatomy
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Summary and general discussion
This thesis focuses on endovascular repair (EVAR) and outcome in patients with 
non-ruptured and ruptured abdominal aortic aneurysms (AAAs), evaluates new 
insights and possibilities for EVAR, and evaluates EVAR in challenging infrarenal 
aortic neck anatomy.
This chapter describes the main findings of this thesis and concludes with the 
limitations of this thesis and some suggestions for future research.
PART ONE - Evolution and long-term follow-up in EVAR
Since the introduction of elective EVAR in 1991 by Parodi and Volodos, followed by 
the introduction of emergency EVAR in 1994 by Yusuf, the endovascular approach 
of AAAs has been applied with increasing frequency.1-4 The endovascular approach 
of AAAs is less invasive than open surgical repair (OR) and demonstrates decreased 
early mortality and morbidity.5,6 PART ONE focuses on the outcome of elective and 
emergency EVAR using a prospective single-centre database. 
The occurrence of graft-related and aneurysm-related complications remains 
the Achilles’ heel of the endovascular approach of abdominal aortic aneurysm 
treatment. Indications to perform secondary interventions are endoleaks, stent graft 
migration, stent fractures and stent graft occlusions.7,8 Current guidelines advise 
lifelong surveillance after EVAR in order to detect EVAR related complications.9 
However, there is limited data on long-term stent graft related complications to 
support this recommendation. This raises the question whether such an extended 
follow-up is really necessary. Chapter 2 evaluated 149 AAA patients treated with 
the Talent Abdominal Stent Graft (Medtronic Vascular, Santa Rosa, CA, USA) with a 
minimum of ten-year follow-up. Technical success, defined as a successful stent 
graft deployment and the absence of type I and III endoleaks, was achieved in 
89.3% of the procedures. The primary outcome was clinical success, defined as 
the absence of aneurysm related death, graft stenosis, occlusion or infection, type 
I or III endoleak, aneurysm expansion, aneurysm rupture, or conversion to open 
repair. In our population, the 30-day, one-year, five-year and ten-year clinical 
success rates were 81.1%, 74.3%, 70.3% and 65.5%, respectively. A total of 20.7% of 
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patients required at least one secondary intervention, which is comparable with 
previous studies. In 70% of the secondary interventions, stent graft failure was 
detected at regular follow-up, as patients were asymptomatic. The outcome of 
this study demonstrated EVAR-related complications during the entire follow-up 
period and therefore justifies surveillance at least up to ten years. 
The technical success of EVAR is highly dependent on accurate preoperative 
planning, including aortic aneurysm sizing and adequate stent graft selection. 
In emergency EVAR, planning has to be done in a restricted time frame with a 
limited availability of stent graft modules. This could hypothetically influence the 
technical outcome. Chapter 3 describes a 15-year single-centre experience of EVAR 
in 773 patients with a non-ruptured AAA and 90 patients with a ruptured AAA. This 
study demonstrates excellent intra-operative success rates of 95.0% in elective 
EVAR and 90.0% in emergency EVAR (p = .052). We found a higher incidence of type 
I endoleaks at completion angiography after emergency EVAR (6.9% vs. 2.8%, p = 
.038). However, the majority of these type I endoleaks resolved spontaneously 
without secondary intervention. In addition, there were no significant differences 
in the need for endograft-related secondary interventions after five years of 
follow-up. As may be expected, the survival rates for all-cause mortality at 5-year 
follow-up were significantly lower after emergency EVAR (48.1% vs. 65.2%, p < .001). 
The outcome of this study indicates that EVAR is technically comparable in elective 
and emergency settings.
PART TWO - Clinical experience and new insights regarding EVAR
Despite more than two decades of experience with EVAR, opinions are still divided 
regarding some aspects of this technique. PART TWO of this thesis focuses on 
the use of different anaesthesia types and emergency EVAR in hemodynamically 
unstable patients.
EVAR can be performed under general, regional and local anaesthesia. There is still 
no consensus on which type of anaesthesia is most suitable. Being less invasive, 
the use of local anaesthesia is preferred according the guideline of the European 
Society of Vascular Surgery.9 However, EVAR is still mainly performed under general 
anaesthesia.10 Chapter 4 examined outcomes of EVAR using general anaesthesia 
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(GA), regional anaesthesia (RA) and local anaesthesia (LA) in 1262 patients. The 
majority of patients were treated under general anaesthesia (GA 62.3%, RA 26.2%, 
LA 11.5%). We reported advantages of local and regional anaesthesia regarding 
procedure time and post-operative stay. Type of anaesthesia used did not 
influence technical success rates. LA resulted in fewer short-term complications, 
however a significant advantage was not established (GA 5.6% vs. RA 4.8% vs. LA 
2.8%). Thirty-day mortality was comparable among groups (GA 1.4% vs. RA 0.9% 
vs. LA 1.4%).
According to a recent meta-analysis, mortality rates in patients with a ruptured AAA 
are estimated at 81%.11 Up to half of the patients who undergo surgical treatment 
will subsequently die in the perioperative period.12 Previous studies reported 
no survival probability in patients requiring preoperative cardiopulmonary 
resuscitation (CPR).13,14 We evaluated 199 patients with an RAAA in three large non-
academic teaching hospitals, and the results are reported in Chapter 5. Twenty-
three RAAA patients (11.6%) did not receive invasive treatment, because they were 
deemed inoperable or were deceased before surgery could be initiated. This turn-
down rate is relatively low in comparison to the literature with turn-down rates of 
up to 40%.15 We identified 13 (7.4%) treated patients who needed preoperative CPR. 
The majority were resuscitated in the hospital (76.9%). A total of 11 CPR patients 
were treated with open aortic surgery (OR), and two CPR patients underwent 
EVAR. Both EVAR patients survived, in contrast to 3/11 of OR patients (p = .128). 
In contrast to the in literature reported 100% mortality in this patient group, 
we found a 30-day survival rate of 38.5% (5/13).13,14 Although no firm conclusions 
can be drawn based on these low numbers, our results suggest that aneurysm 
treatment in hemodynamically unstable patients is still feasible and that EVAR 
may be preferred over open repair. 
PART THREE - Challenging anatomy in EVAR
Anatomic suitability for EVAR is defined by the manufacturers’ instructions for use 
(IFU) and remains one of the main reasons for treating an AAA via open surgery. 
However, contemporary stent grafts are used in challenging aortic neck situations 
exceeding the IFU limitations. PART THREE focuses on elective and emergency 
EVAR in challenging aortic neck anatomies.
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There have been reports that up to 80% of patients with an RAAA are regarded not 
suitable for EVAR.16 In Chapter 6, we compare the midterm results of EVAR for RAAAs 
in patients with favourable (FNA) and challenging neck anatomy (HNA) according 
the IFU. An EVAR-first strategy was followed for RAAA repair. A total of 39 patients 
were included who primarily underwent endovascular treatment. Challenging 
neck anatomy was present in 43.6%. Technical success was comparable (FNA 100% 
vs. HNA 88.2%, p = .184). There was no type I endoleak at completion angiography 
in any of the groups, but the HNA group required significantly more adjunctive 
procedures to resolve an intra-operative type IA endoleak (23.5% vs. 0%, p = .029). 
There were no significant differences between groups at one-year follow up in type 
I endoleaks, secondary endovascular procedures and all-cause mortality. These 
excellent results indicate that EVAR applicability in RAAAs with challenging neck 
anatomy is technically feasible and safe in experienced endovascular centres. 
Chapter 7 compares outcomes of EVAR in patients with various neck morphologies 
in an elective setting. Data from the ENGAGE Registry were used for the analyses. 
Patients were categorized into three groups, based on the complexity of the 
proximal aortic neck: regular (REG), intermediate (INT) and challenging (CHA). 
There were no significant differences in operative technical success. The 30-
day incidence of type I endoleaks was significantly higher in patients with CHA 
anatomy compared to INT and REG anatomy (REG vs. CHA: OR 0.15, 95% CI 0.05-
0.46 and INT vs. CHA: OR 0.08, 95% CI 0.01-0.70). Surprisingly this difference did 
not result in more secondary interventions. Most type I endoleaks were small and 
resolved spontaneously. At 1-year follow-up, there were no differences in type I 
endoleaks, secondary interventions or mortality among groups. Based on these 
data, we can conclude that patients with severely angulated and short infrarenal 
necks can be treated successfully with the Endurant Stent Graft. 
The performance of the Endurant Stent Graft in challenging anatomy is evaluated 
in many reports, showing no differences in operative success and early outcome.17-19 
However, these studies consisted of (relatively) small, retrospectively collected 
patient groups with possible selection bias. Therefore, the Endurant for challenging 
Anatomy: GLobal Experience (EAGLE) Registry was initiated to prospectively collect 
global ‘real-world’ performance data on the Endurant Stent Graft in anatomically 
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challenging aneurysms and to critically assess whether the current guidelines for 
anatomic eligibility for EVAR are still applicable if EVAR is performed with this 
system. The penultimate chapter of this thesis (Chapter 8) describes the rationale 
and design of the EAGLE Registry. Initiated by doctors, EAGLE is a prospective, non-
interventional study, aiming to enrol 250 patients with a challenging anatomy in at 
least 20 experienced vascular centres worldwide. Ruptured AAAs will be excluded. 
To minimize the risk of selection bias, anatomic eligibility will be determined by 
an independent core laboratory, and efforts will be made to secure consecutive 
enrolment. The primary endpoint is technical success at 30 days, 1 year and yearly 
up to five years post-implant. EAGLE aims to complete enrolment in 2016. 
Study limitation and future perspectives
PART ONE - Evolution and long-term follow up in EVAR
A quarter of a century has passed since Parodi and Volodos introduced the 
endovascular repair of AAA.1 The Achilles’s heel of EVAR remains the high rate of 
secondary interventions. Lifelong follow-up requires a great investment of time 
and resources, while the majority of these patients do not require any further 
intervention. It would be desirable to identify patients with a significantly higher 
risk for complications and provide these patients with an extensive follow-up. 
Our data analysis could not identify predictors for graft-related complications 
or secondary interventions. The success of EVAR is closely dependent on AAA 
morphology and aortic dimensions. However, anatomical data was missing in our 
study.20
There is an ever need for improved stent grafts and endovascular techniques 
to increase the durability and safety of EVAR. In the past few years, the focus 
of improvements has been mainly on deliverability, placement accuracy and 
tight sealing to reduce graft-related complications and the need for secondary 
interventions. With continuous refinement of both the stent graft and its delivery 
system, and with the increasing experience of physicians, the outcome and 
applicability of EVAR will continue to improve in the future.21
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PART TWO Clinical experience and new insights regarding EVAR
We described fewer systemic complications for the use of local anaesthesia, but 
no significant advantage of local anaesthesia was established. This could be 
explained by the low incidence of complications after EVAR. A much larger study 
population is necessary to demonstrate clinical differences between anaesthesia 
types. Local anaesthesia did result in shorter procedure time and shorter post-
operative stay. The standard use of local anaesthesia during EVAR procedures 
could reduce treatment costs in the future. 
We described survivors after CPR prior to RAAA surgery, which is in contrast to 
previous studies that described 100% mortality in this patient group. Of the 
survivors, two patients were treated with EVAR and three with open surgical 
repair. Due to these small numbers, we were unable to conclude if EVAR is better 
than open repair. However, one might expect that a minimally invasive treatment 
under local anaesthesia with a shorter operating time, less bloodloss en no need 
for aortic cross clamping will result in better outcome. Future research with more 
patients is necessary to investigate if a minimally invasive approach may be 
preferred in highly unstable patients. 
PART THREE - Challenging anatomy in EVAR
We did not investigate whether EVAR or open surgical repair is better for patients 
with challenging aortic anatomies. The optimal study design for answering this 
question is a randomized controlled trial comparing open repair with EVAR. 
However, one must question if such an RCT design is feasible in view of the 
contemporary preference for EVAR. Moreover, RCT results may not reflect ‘real 
world’ outcome since patient inclusion is often subject to strict inclusion criteria. 
The ENGAGE registry will contain a great number of data regarding the real world 
performance of a latest generation stent graft system. Based on this database, 
on current literature and on our own experience, it seems that a great share of 
EVAR patients are actually treated outside of IFU criteria. Although a great number 
of surgeons do so, at least apparently, no evidence exists on the ‘rightful’ use 
of these devices outside IFU. Unfortunately, the number of challenging cases in 
ENGAGE has not enough power to perform a sub-analysis to test for non-inferiority 
of these challenging cases. With the EAGLE registry, which has a similar design 
as ENGAGE, we aim to expand the subgroup of challenging cases in an effective 
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way so we can perform an adequate analysis. We aim to answer the question if 
the technical success rate and the successful treatment rate are comparable in 
anatomically challenging aneurysms. 
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Dit proefschrift richt zich op de uitkomsten van de endovasculaire (via de binnenzijde 
van het bloedvat) reparatie (EVAR) van aneurysmata van de abdominale aorta 
(AAA). Dit proefschrift is onderverdeeld in drie delen. De resultaten van EVAR in 
patiënten met niet-geruptureerde en geruptureerde AAAs worden geanalyseerd in 
het eerste deel. Vervolgens worden nieuwe inzichten en mogelijkheden van EVAR 
geanalyseerd. In het laatste deel wordt de toepasbaarheid van EVAR in complexie 
aorta anatomie getoetst. Dit hoofdstuk beschrijft de belangrijkste bevindingen 
van dit proefschrift.
DEEL ÉÉN - Evolutie en lange-termijn resultaten van EVAR
De eerste EVAR procedure vond plaats in 1991 door Parodi in Argentinië en Volodos 
in Oekraïne.1,2 In 1994 werd de eerste acute EVAR uitgevoerd bij een geruptureerd 
AAA door Yusuf.3 Over de afgelopen 25 jaar wordt EVAR in toenemende mate 
toegepast voor de behandeling van een AAA. De endovasculaire behandeling is 
minder invasief dan de ‘open’ chirurgische behandeling. Er wordt gebruik gemaakt 
van een speciaal implantaat, een zogenaamde endovasculaire stentgraft. Uit 
eerder onderzoek is gebleken dat EVAR resulteert in minder vroegtijdige sterfte 
en morbiditeit ten opzichte van de open chirurgische behandeling.4,5 Het eerste 
deel van dit proefschrift analyseert de uitkomst van electieve en acute EVAR 
procedures gebaseerd op een prospectieve, single center studie. 
Ondanks uitstekende resultaten met betrekking tot vroegtijdige sterfte en 
morbiditeit van EVAR, kent deze techniek ook complicaties welke uniek zijn voor 
deze behandeling. Het optreden van stentgraft-gerelateerde complicaties, met 
vaak een secundaire behandeling (revisie) als gevolg, blijft het grootste nadeel 
van deze techniek. Complicaties die een secundaire behandeling behoeven zijn 
endoleaks, migratie en occlusie van de stentgraft.6,7 Een endoleak is een lekkage 
van bloed in de aneurysmazak, waardoor het aneurysma weer onder druk komt 
te staan met het daarmee geassocieerde risico van een ruptuur. De huidige 
richtlijnen adviseren levenslange controle omdat deze complicaties jaren na de 
endovasculaire procedure kunnen ontstaan.8 Er is echter weinig beschreven over 
de lange termijn resultaten die deze aanbevelingen ondersteunen. De eventuele 
158 Chapter 10
noodzaak voor een lange termijn controle wordt geanalyseerd in hoofdstuk 2. 
Dit hoofdstuk evalueert 149 patiënten met een AAA die behandeld zijn met de 
Talent™ stentgraft (Medtronic Vascular, Santa Rosa, CA, USA) met een minimale 
opvolging van tien jaar. Technisch succes, gedefinieerd als succesvolle stentgraft 
plaatsing met de afwezigheid van een type 1 en/of 3 endoleak, werd bereikt 
in 89.3% van de patiënten. De primaire uitkomstmaat was klinisch succes, 
gedefinieerd als de afwezigheid van aneurysma-gerelateerde sterfte, stentgraft 
stenose, occlusie of infectie, type 1 en/of 3 endoleak, aneurysma groei, aneurysma 
ruptuur of de noodzaak tot conversie naar de open chirurgische behandeling. De 
klinische succes percentages na 30-dagen, één-jaar, vijf-jaar en tien jaar waren 
respectievelijk 81.1%, 74.3%, 70.3% en 65.5%. Tijdens de totale opvolging werd 
in verband met stentgraft-gerelateerde complicaties bij 20.7% van de patiënten 
op zijn minst één secundaire procedure uitgevoerd, wat vergelijkbaar is met de 
resultaten in eerder gepubliceerde studies. In 70% van deze complicaties waren 
de patiënten asymptomatisch en werd de complicatie gezien op beeldvorming 
tijdens de reguliere opvolging. Uit deze studie kunnen we dan ook concluderen 
dat stentgraft-gerelateerde complicaties tijdens de eerste tien jaar na EVAR niet 
zeldzaam zijn en in de meeste gevallen bij regulier beeldvormend follow-up 
onderzoek worden gedetecteerd. Deze bevinding rechtvaardigt onze inspanningen 
bij de opvolging van EVAR patiënten voor tenminste de eerste tien jaar post-
operatief.
Het technisch succesvol uitvoeren van een EVAR procedure is sterk afhankelijk 
van nauwkeurige preoperatieve planning. Dit omvat onder andere het opmeten 
van de aorta en het uitkiezen van de juiste maat stentgraft. In het geval van 
een geruptureerd AAA (acute EVAR) moet deze planning in een beperkte tijd 
plaatsvinden in verband met de instabiliteit van de patiënt op dat moment. Ook 
zal de juiste maat stentgraft gekozen moeten worden uit een (relatief) beperkt 
assortiment wat op dat moment in het ziekenhuis aanwezig is. Hypothetisch 
gezien kunnen deze factoren de technische uitkomst van een EVAR procedure 
negatief beïnvloeden. Hoofdstuk 3 evalueert de uitkomsten van EVAR procedures 
bij 773 patiënten met een niet-geruptureerd AAA (E-EVAR) en 90 patiënten met 
een geruptureerd AAA (R-EVAR). Deze studie laat uitstekende resultaten zien 
met een operatief succes percentage van 95% in de E-EVAR groep en 90.0% in 
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de R-EVAR groep (p = 0.052). Er werden significant meer type I endoleaks op de 
completering angiografie gezien in de R-EVAR groep ten opzichte van de E-EVAR 
groep (6.9% vs. 2.8%, p = 0.038). Echter, de meerderheid van deze type I endoleaks 
verdween spontaan zonder de noodzaak van een secundaire interventie. Er 
waren geen significante verschillen tussen beide groepen in de hoeveelheid 
secundaire interventies na vijf jaar follow-up. Zoals men kon verwachten was 
de vijfjaarsoverleving lager in de R-EVAR groep (65.2% vs. 48.1%, p < 0.001). Deze 
studie laat zien dat de resultaten van EVAR procedures in een electieve en spoed 
setting technisch vergelijkbaar zijn.
DEEL TWEE - Klinische ervaring en nieuwe inzichten ten aanzien van EVAR
Meer dan twee decennia na de introductie van EVAR zijn de meningen nog 
steeds verdeeld over een aantal aspecten van deze techniek. Deel twee van dit 
proefschrift richt zich op het gebruik van verschillende anesthesie technieken en 
op EVAR bij hemodynamisch zeer instabiele, gereanimeerde patiënten. 
Een EVAR procedure kan onder algehele, regionale (spinaal/epiduraal) en lokale 
anesthesie worden uitgevoerd. Er is geen consensus over welk type anesthesie 
het meest geschikt is voor EVAR. De richtlijn van de European Society of Vascular 
Surgery geeft de voorkeur aan de minder invasieve lokale anesthesie.8 Ondanks 
deze aanbeveling wordt EVAR voornamelijk onder algehele anesthesie verricht.9 
Hoofdstuk 4 vergelijkt de resultaten van EVAR onder algehele anesthesie (GA), 
regionale anesthesie (RA) en lokale anesthesie (LA) in 1262 patiënten. De meeste 
patiënten werden behandeld onder algehele anesthesie (GA 62.3%, RA 26.2%, LA 
11.5%). Lokale en regionale anesthesie resulteerden in een kortere operatie tijd 
en een korter postoperatief verblijf in het ziekenhuis ten opzichte van algehele 
anesthesie. Het type anesthesie had geen invloed op het technisch operatief 
succespercentage. Patiënten in de lokale anesthesie groep hadden minder korte 
termijn complicaties, echter niet significant verschillend ten opzichte van de 
andere twee groepen (GA 5.6 vs. RA 4.8% vs. LA 2.8%). De sterfte in de eerste 30 
dagen na EVAR was vergelijkbaar tussen de groepen (GA 1.4% vs. RA 0.9% vs. LA 
1.4%).
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Het sterftecijfer van patiënten met een geruptureerd AAA is ongeveer 81% volgens 
een recente meta-analyse.10 Tot ongeveer 50% van de patiënten met een ruptuur 
die behandeld worden overlijdt in de perioperatieve periode.11 Eerdere studies 
rapporteerden 100% sterfte bij patiënten die gereanimeerd zijn voordat ze 
geopereerd worden en concludeerden dat een operatieve behandeling in deze 
patiëntengroep niet zinvol is.12,13 Om deze aanbeveling te toetsen evalueerden we 
199 patiënten met een geruptureerd AAA die behandeld werden in drie grote, niet-
academische ziekenhuizen in Nederland. De resultaten van deze studie worden 
geëvalueerd in hoofdstuk 5. Drieëntwintig patiënten (11.6%) met een ruptuur 
ondergingen geen operatieve behandeling omdat de overlevingskans te klein 
werd ingeschat, door de aanwezigheid van comorbiditeit of ze waren al overleden 
voordat een operatie gestart kon worden. In de literatuur worden percentages tot 
40% beschreven van patiënten met een ruptuur die geen operatieve behandeling 
ondergaan.14 Van de 199 geïncludeerde patiënten werden 13 patiënten (7.4%) 
gereanimeerd voor het moment van operatie. De meeste patiënten in deze 
groep werden gereanimeerd in het ziekenhuis (76.9%). Hiervan ondergingen 11 
patiënten open aorta chirurgie (OR) en twee patiënten werden endovasculair 
behandeld (EVAR). Beide EVAR patiënten overleefden het in tegenstelling tot 8/11 
OR patiënten (p = 0.128). In tegenstelling tot de in de literatuur gerapporteerde 
sterfte van 100%, vonden wij een 30-dagen overleving van 38.5%.12,13 Hoewel geen 
definitieve conclusies kunnen worden getrokken op basis van de lage aantallen 
in deze studie, suggereren onze resultaten dat succesvolle operatieve AAA 
behandeling in hemodynamisch zeer instabiele patiënten haalbaar is. EVAR heeft 
daarbij mogelijk de voorkeur boven open chirurgie. 
DEEL DRIE - EVAR in patiënten met complexe aorta anatomie
De anatomie van de abdominale aorta en het aneurysma verschilt per individu. De 
anatomische geschiktheid voor EVAR is per stentgraft beschreven in de instructies 
van de fabrikant. Veel patiënten vallen buiten deze anatomische criteria en dit 
blijft één van de belangrijkste redenen voor de behandeling van AAAs via open 
chirurgie. De lengte en angulatie van de proximale infrarenale hals van de aorta zijn 
hierbij belangrijke anatomische criteria. Uit onderzoek is gebleken dat chirurgen 
steeds vaker AAAs endovasculair behandelen met kenmerken die buiten de door 
de fabrikant opgestelde anatomische criteria vallen. Toenemende ervaring met 
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EVAR en verbeterde stentgrafts laten dit waarschijnlijk ook toe, maar concreet 
bewijs is beperkt. Het derde deel van dit proefschrift richt zich op de electieve en 
spoed EVAR bij patiënten met complexe anatomie van de infrarenale hals.
Ongeveer 80% van de patiënten met een geruptureerd aneurysma is niet geschikt 
voor EVAR op basis van de anatomie van de aorta en het aneurysma.15 In hoofdstuk 
6 worden de resultaten van EVAR vergeleken bij patiënten met een geruptureerd 
AAA met een niet-complexe (FNA) en complexe (HNA) anatomie van de infrarenale 
hals. Het onderscheid werd gemaakt op basis van de anatomische criteria van de 
geïmplanteerde stentgraft. Er werd een behandelstrategie gevolgd waarbij EVAR de 
voorkeur kreeg boven open chirurgie. In totaal zijn 39 patiënten met een ruptuur 
geïncludeerd die een primaire endovasculaire behandeling ondergingen. In 43.6% 
van de patiënten was sprake van complexe anatomie van de infrarenale hals. Het 
technisch operatief succes percentage was vergelijkbaar in beide groepen (FNA 
100% vs. HNA 88.2%, p = 0.184). Aan het eind van de procedure werden in beide 
groepen geen type I endoleaks op de angiografie gezien. Wel waren in de HNA 
groep meer additionele procedures nodig om peroperatieve type I endoleaks op 
te lossen (0% vs. 23.5%, p = 0.029). Een jaar na de procedure was er geen verschil 
in type 1 endoleaks, secundaire endovasculaire procedures en sterfte tussen de 
groepen. Deze uitstekende resultaten geven aan dat EVAR technisch haalbaar en 
veilig is bij patiënten met een geruptureerd AAA met complexe anatomie van de 
infrarenale hals in ervaren endovasculaire centra. 
Hoofdstuk 7 beschrijft de invloed van infrarenale hals anatomie op electieve 
EVAR. Gegevens van 1218 patiënten uit de (ENGAGE) Registry werden gebruikt voor 
deze analyse.16 De patiënten werden verdeeld in drie groepen op basis van de 
complexiteit van de infrarenale aorta hals; ‘regular’ (REG), ‘ intermediate’ (INT) 
en ‘challenging’ (CHA). De mate van angulatie en lengte van de infrarenale hals 
bepaalden de mate van complexiteit. Er waren geen significante verschillen tussen 
de groepen met betrekking tot technisch operatief succes. De incidentie van type 
I endoleaks was significant hoger in de CHA groep in vergelijking met INT en REG 
anatomie (REG vs. CHA: OR 0.15, 95% BI 0.05 – 0.46 en INT vs. CHA: OR 0.08%, 95% 
BI 0.01-0.70). Dit verschil resulteerde echter niet tot meer secundaire interventies. 
De meeste type I endoleaks waren minimaal en verdwenen spontaan. Een jaar 
na de procedure waren er geen significante verschillen tussen de groepen met 
162 Chapter 10
betrekking tot type I endoleaks, secundaire interventies en sterfte. Op basis van 
deze resultaten kan geconcludeerd worden dat patiënten met ernstig geanguleerde 
en korte infrarenale halzen succesvol endovasculair behandeld kunnen worden 
met de Endurant Stent Graft (Medtronic Vascular, Santa Rosa, Calif ).  
De uitkomsten van de Endurant Stent Graft in complexe anatomie is al in veel 
publicaties beschreven, waarin geen significant verschillen worden gerapporteerd 
met betrekking tot technisch operatief succes en korte termijn resultaten.17-19 
Deze studies bestonden uit (relatief) kleine en retrospectief verzamelde 
patiëntengroepen waarbij mogelijk sprake is van selectiebias. De ‘Endurant 
for challenging Anatomy: GLobal Experience (EAGLE) Registry’ werd geïnitieerd 
om prospectief ‘real-world’ data te verzamelen over de Endurant Stent Graft in 
patiënten met complexe anatomie van de infrarenale hals. Hiermee kunnen de 
huidige anatomische criteria voor EVAR getoetst worden en de mogelijkheden 
worden geëvalueerd of meer patiënten middels EVAR behandeld kunnen worden. 
Hoofdstuk 8 beschrijft het doel en het studie ontwerp van de EAGLE Registry. Deze 
studie is geïnitieerd door artsen. EAGLE is een prospectieve, niet-interventionele 
studie met als doel om 250 patiënten met complexe infrarenale hals anatomie te 
includeren in minimaal 20 ervaren vasculaire centra wereldwijd. Geruptureerde 
AAAs worden geëxcludeerd in deze studie. Inclusie zal bepaald worden op basis 
van metingen door een onafhankelijk CORE lab om selectiebias te minimaliseren. 
De primaire uitkomsten zijn technisch succes op 30 dagen, een jaar en vervolgens 
jaarlijks tot maximaal vijf jaar na de procedure. Het doel van EAGLE is om inclusie 
te voltooien in het voorjaar van 2016.  
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Een aneurysma van de abdominale aorta (AAA) is een lokale verwijding van de 
buikslagader. We spreken van een AAA indien de diameter ten minste 1.5 maal groter 
is dan de verwachte diameter van het betreffende bloedvat. Een andere definitie 
is op basis van de bovengrens van de normale diameter van de abdominale aorta 
die voor mannen en vrouwen 2.9 cm is. Bij deze definitie is afgesproken dat bij een 
diameter  groter of gelijk aan 3.0 cm sprake is van een aneurysma. 
De prevalentie van een AAA is hoger bij mannen dan bij vrouwen. De prevalentie 
bij mannen is 1.3% tot 8.9% en bij vrouwen 1.0% tot 2.2%. Belangrijke risicofactoren 
voor het ontstaan van een AAA zijn leeftijd, geslacht en roken. 
Een AAA vormt een levensbedreigend risico als sprake is van een ruptuur. Hierbij 
ontstaat een scheur in de aorta waardoor een potentieel levensbedreigende 
bloeding ontstaat. Na een ruptuur overlijdt ongeveer 80% van de patiënten, 
hiervan overlijdt de helft voordat ze het ziekenhuis bereiken. Bij vrouwen is de 
kans op ruptuur groter dan bij mannen.
De behandeling is afhankelijk van de diameter van het AAA en co-morbiditeit van 
de patiënt. Bij een AAA kleiner dan 5.5 cm (bij de vrouw kleiner dan 5.0 cm) zal het 
AAA echografisch worden vervolgd met een frequentie afhankelijk van de diameter. 
In het geval van snelle groei of bij klachten kan overgaan worden tot behandeling. 
Bij een diameter van 5.5 cm (bij een vrouw 5.0 cm) of bij een snelle groei (meer 
dan 1 cm per jaar) zal bij de meeste patiënten worden overwogen om te opereren, 
omdat vanaf deze diameter het operatierisico kleiner is dan het risico op een 
ruptuur. In het geval van een ruptuur is directe operatieve behandeling gewenst. 
Afhankelijk van onder andere de anatomie van het aneurysma kan een keuze 
worden gemaakt voor een open operatie of een endovasculaire operatie (EVAR). 
Gezien de lagere perioperatieve mortaliteit verdient, indien anatomisch mogelijk, 
EVAR de voorkeur. Bij een EVAR wordt een stentgraft via de lies ingebracht en 
opgevoerd totdat de stent ter hoogte van het aneurysma ligt. De stentgraft wordt 
in het aneurysma geplaatst om zo het aneurysma af te sluiten van de normale 
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bloedstroom. Deze procedure kan onder lokale anesthesie verricht worden.
Bij een open operatie wordt het AAA van buitenaf benaderd middels een grote 
incisie in de buik van de patiënt. Het aneurysma wordt vervolgens chirurgisch 
afgesloten van het hoofddeel van de aorta en vervangen door een kunststof 
buisprothese, die wordt in gehecht. Dit is een invasieve procedure met een 
aanzienlijke mortaliteit en morbiditeit. De open operatie wordt altijd onder 
algehele narcose uitgevoerd.
Dit proefschrift heeft als doel om de mogelijkheden van EVAR te beschrijven en 
om de anatomische grenzen van EVAR te toetsen. Om dit doel te bereiken werden 
diverse wetenschappelijke studies verricht. 
Een patiënt met een AAA is vaak op leeftijd met soms een uitgebreide comorbiditeit. 
Onderzoek in dit proefschrift heeft aangetoond dat EVAR uitgevoerd kan worden 
met behulp van lokale anesthesie. Dit is een groot voordeel ten opzichte van de 
open chirurgische behandeling die alleen uitgevoerd kan worden onder algehele 
narcose wat risico’s met zich meebrengt. Een minimaal invasieve operatie onder 
minimaal belastende anesthesie moet een streven worden voor alle patiënten 
met een AAA in de toekomst. 
Na een EVAR procedure kan de patiënt eigenlijk na een paar uur al naar huis. 
Een EVAR als dagbehandeling wordt in het buitenland al veel toegepast met 
uitstekend resultaten. Patiënten kunnen vervolgens thuis herstellen en worden 
zo niet blootgesteld aan de risico’s van een ziekenhuisopname. Dit zorgt er 
uiteindelijk ook voor dat in het ziekenhuis meer bedden beschikbaar zijn voor 
andere patiënten. Ook kunnen de kosten van een EVAR behandeling gereduceerd 
worden. Deze vorm van zorg kan in Nederland verzekeringstechnisch helaas nog 
niet worden uitgevoerd. Vanuit doelmatigheid oogpunt valt hier in de toekomst 
nog winst te behalen bij de behandeling van het AAA. 
De keuze of een AAA patiënt een endovasculaire of open chirurgische behandeling 
krijgt is niet alleen gebaseerd op anatomische geschiktheid. De ervaring van de 
vaatchirurg die deze anatomische geschiktheid beoordeelt speelt hierbij een 
171Valorisatie addendum
grote rol. Uit recente AAA-studies blijkt dat veel centra nog een substantieel 
deel van hun patiënten middels de invasieve open chirurgie behandelen. In het 
Catharina ziekenhuis, waar het grootste deel van de patiënten uit dit proefschrift 
zijn behandeld, wordt nog maar een fractie van de patiënten behandeld met open 
chirurgie. Er bestaat dus nog veel discrepantie tussen verschillende ziekenhuizen 
en het is dan ook de vraag of het advies uit de Nederlandse richtlijn om, indien 
anatomisch mogelijk voor EVAR te kiezen, altijd wordt opgevolgd. 
De criteria waaraan de anatomie moet voldoen om voor EVAR in aanmerking te 
komen is per stentgraft beschreven in de door de fabrikant opgestelde instructies 
voor gebruik (Engels: Instructions for use [IFU]). Een aanzienlijk aantal AAA 
patiënten valt buiten deze anatomische criteria en wordt niet geschikt bevonden 
voor een endovasculaire behandeling. Helaas zijn deze patiënten ook vaak in 
een dusdanig slechte conditie dat ze geen open operatie aan kunnen. Hierom is 
de continue doorontwikkeling van stentgrafts essentieel om zo de anatomische 
criteria te verruimen en meer patiënten met deze minimaal invasieve techniek 
te kunnen behandelen. Er ligt hier dus een uitdaging voor de medische industrie 
en de medische wetenschap om het percentage patiënten geschikt voor EVAR zo 
groot mogelijk te maken.
De Endurant for challenging Anatomy: GLobal Experience (EAGLE) registry heeft 
als doel om data te verzamelen over een van de laatste generaties stentgraft in 
patiënten met complexe anatomie van de infrarenale hals (Endurant, Medtronic 
AVE, Sant Rosa, Ca, USA). Omdat de in deze registry participerende, ervaren 
endovasculaire centra de IFU regelmatig worden overschreden zonder dat zich 
hierbij problemen voordoen, worden deze patiënten nu verzameld in de EAGLE 
registry. Deze registry maakt het mogelijk de anatomische criteria voor EVAR te 
evalueren en zo de mogelijkheden te toetsen om in de toekomst meer patiënten 
middels EVAR veilig te behandelen. De EAGLE Registry is uniek omdat zij geïnitieerd 
is door endovasculaire chirurgen zelf. 

Dankwoord

175Dankwoord
Dankwoord
Een proefschrift schrijf je niet alleen. Veel mensen hebben direct of indirect een 
bijdrage geleverd aan de inhoud van dit proefschrift. Een aantal van hen wil ik 
graag persoonlijk bedanken.
Prof. dr. J.A.W. Teijink, beste promotor, beste Joep, allereerst wil ik jou bedanken. Ik 
ben je zeer dankbaar dat je mij de mogelijkheid hebt gegeven om te promoveren. 
Dit proefschrift was niet mogelijk geweest zonder jouw passie voor de vaatchirurgie 
en de wetenschap. Jouw energie en hoeveelheid aan ideeën zijn ongekend. 
Hierdoor heb ik mijn promotie snel af kunnen ronden. Niet alleen op het werk 
maar ook daar buiten was het altijd gezellig. Je stond altijd vooraan bij de vele 
vaatuitjes en de jaarlijkse congressen met de gehele vaatclub. Al met al was het 
een fantastische en leerzame tijd! Ik hoop dat ik nog lang betrokken mag blijven 
bij het AAA onderzoek in het Catharina Ziekenhuis.
Dr. M.R.H.M. van Sambeek, beste copromotor, beste Marc, wat heb ik een geluk met 
jou als copromotor. Bedankt dat je altijd de tijd hebt genomen om kritisch naar 
mijn artikelen te kijken. Waar ik vaak totaal de weg kwijt was kon jij mij weer in 
de juiste richting sturen. Jouw vertrouwen in mijn onderzoek gaf mij de motivatie 
om door te gaan. De congressen in onder andere Miami en New York waren een 
geweldige ervaring. 
Dr. Ph.W.M. Cuypers, beste copromotor, beste Philippe, bedankt voor al je inzet 
tijdens mijn promotie. Ik kon altijd aankloppen met vragen en steeds nam je de 
tijd om de publicaties naar een hoger niveau te tillen. Het is een eer om met 
iemand samen te mogen werken die zoveel ervaring in de aortachirurgie heeft.. 
Samen met jou op congres in Miami was geweldig. Wat hebben we een lol gehad. 
Bedankt! 
Alle mede-auteurs, bedankt voor jullie inzet bij mijn publicaties. Zonder jullie 
geen promotie! In het bijzonder wil ik ook Saskia Houterman bedanken. Bedankt 
voor je eeuwige geduld. 
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Graag zou ik de leden van de beoordelingscommissie, voorzitter prof. dr. M.H. 
Prins, prof. dr. F.L. Moll, prof. dr. G.W.H. Schurink en prof. dr. H.J.M. Verhagen willen 
bedanken voor de tijd die jullie hebben genomen voor de kritische beoordeling 
van mijn proefschrift. 
The EAGLE participators. I would like to thank all the doctors and research nurses 
that are part of the EAGLE Registry. Thank you for your great hospitality during my 
visits. It was a great and unique experience! 
Eric Alberts, beste Eric, fantastisch dat jij tijd vrij wilde maken om de lay-out van 
dit boekje op je te nemen. Het is mooier geworden dan ik had durven dromen. 
Ontzettend bedankt!
Toon van der Krieken, beste Toon, geweldig om te mogen leren van iemand die 
zoveel ervaring heeft met EVAR en beeldvorming. Dit zorgde voor een geweldige 
bijdrage aan meerdere  hoofdstukken in dit proefschrift. Ook bedankt voor je 
inzet en vertrouwen in de EAGLE Registry.
Gert-Jan Lauret, beste Gert-Jan, goede vriend, collega, trainingsmaatje en 
paranimf! Fantastisch dat ik jou heb leren kennen. Bedankt voor al je tips en steun 
bij de afronding van mijn promotie. Wat heb ik met jou vaak hard mogen lachen 
tijdens alle uitstapjes en congressen. De tripjes naar Budapest en Porto waren 
veruit hoogtepunten. Nu mijn promotie klaar is kijk ik er naar uit om het oude 
trainingsritme weer op te pakken. Fel zijn! 
Rutger Stokmans, beste Rutger. Als semi-arts heb ik ontzettend veel van jou mogen 
leren. Jouw oog voor perfectie brengt alles tot een hoger niveau. Samen vormden 
we al snel de aortaboys, wat onder andere tot de EAGLE Registry heeft geleid. Ook 
wist jij er altijd een mooi feestje van te maken. De late avondjes in Londen en 
Budapest waren legendarisch. Bedankt voor de mooie tijd!
Onderzoekers van de chirurgie. Hugo, ontzettende baas, wat hebben we een hoop 
lol gehad in het kleine onderzoek hok bij de oude poli chirurgie. Wat zitten ze 
er tegenwoordig luxe bij he! Bedankt dat je altijd bereid was om me te helpen 
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met mijn onderzoek. Yannick, mooi dat jij de AAA-trein voortzet. Heel veel succes 
met jouw proefschrift en de afronding van EAGLE. Ik hoop dat ik nog lang bij het 
AAA-onderzoek betrokken mag blijven. Thijs, tegelijk begonnen aan het schrijven 
van een proefschrift. De snelheid waarin jij gepubliceerd hebt is ongekend. Het 
motiveerde mij om ook zo snel mogelijk dit proefschrift af te ronden. Nu zijn we 
weer collega’s bij de chirurgie. Martin, ik ken niemand die meer bijnamen heeft 
dan jij. Wat kon ik daar toch altijd hard om lachen. Bedankt voor je gezelligheid 
en oprechtheid. Hopelijk is jouw proefschrift ook snel af! Geert, een jaartje mijn 
trouwe buurman in de kelder geweest. Succes met de laatste loodjes van jouw 
boekje!
De maatschap chirurgie en de arts-assistenten van het Catharina Ziekenhuis. Door 
jullie heb ik veel plezier in mijn werk. Dit gaf mij iedere keer weer energie om dit 
boekje af te maken. Bedankt voor jullie steun.
Mijn vrienden. In het bijzonder: Erik, Teun, Thijs, Alex, Ward, Remo en Stijn. 
Bedankt voor de mooie momenten de afgelopen jaren. Laten we de lijntjes lekker 
kort houden! Jasper, heel veel succes met het afronden van jouw promotie in 
Maastricht!
Mijn schoonfamilie, Guido, Godelief, Ben en Kim. Bedankt voor jullie interesse en 
onvoorwaardelijke steun. Jullie staan altijd voor mij, An en Lola klaar. Ontzettend 
bedankt! 
Lieve Hans, fantastisch dat je paranimf bent! Een grote eer om mijn grote broer 
naast me te hebben staan tijdens mijn promotie. Ik kan me geen betere broer 
wensen. Ik kijk ook uit naar de afronding van jouw promotie, zet hem op! Ook wil 
ik mijn schoonzus Madeleine en neefje Lothar bedanken, jullie maken de familie 
compleet! 
Lieve papa en mama, tijdens mijn promotietraject zijn jullie opa en oma geworden! 
Bedankt dat jullie altijd voor mij en mijn gezin klaar staan. Het is altijd een 
feest als ik bij jullie ben! Veel interesse hebben jullie de afgelopen jaren in mijn 
promotieonderzoek getoond. Dit motiveerde mij om dit boekje af te ronden. Jullie 
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zijn de liefste ouders, bedankt!
Tot slot wil ik mijn meisjes bedanken. Lieve An, de grootste overwinning in mijn 
leven dat ben jij. Wat kunnen wij elkaar toch goed aanvullen. Ik geniet van ieder 
moment dat ik bij jou ben. Samen op dezelfde dag promoveren, daar ben ik 
ontzettend trots op. Met jou kan ik heel de wereld aan. Ik zie u heel graag schat! 
Lieve Lola, ons kleintje. Ons mooiste bezit en de vrolijke noot van de familie! Wat 
hou ik toch veel van jou.
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